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ABSTRACT 
 
Effect of n-3 PUFAs on Markers of Inflammation in Arthritic  
 
Horses. 
 
(August 2007) 
 
Denise Rae Manhart, B.S., Oregon State University 
 
Co-Chairs of Advisory Committee: Dr. Brett Scott  
    Dr. Pete Gibbs 
 
Sixteen horses with at least one arthritic joint were randomly divided into two 
groups.  The control group (n=8) was fed a control ration at 1% BW in grain. The 
treatment group (n=8) was fed an isocaloric diet similar to the control diet with 
additional n-3 polyunsaturated fatty acids (PUFAs) in the form of two pelleted 
supplements.  Coastal hay was fed free choice, and both groups consumed their 
respective diet for 90 days.   
On d 0, 30, 60, and 90 synovial fluid was collected from one arthritic joint on 
each horse, and blood samples were collected every 15 days.  Synovial fluid was 
analyzed for Tumor Necrosis Factor-α, Interleukin-1, and white blood cell 
concentration, and plasma was analyzed for fibrinogen and Prostaglandin E2. Force plate 
analysis was used to determine changes in weight distribution throughout the trial.  
 Fatty acid analysis revealed the main n3 supplied by the supplements was 
docosahexaenoic acid (C22:6n3).  Treatment horses consumed 9.3 g docosahexaenoic 
acid daily, while control horses consumed only 0.42 g daily. A reduction in concentrate 
intake also allowed treatment horses to consume 25.45 g less of linoleic acid (C18:2n6) 
iv 
   
 
 
per day.  Excluding hay, the n6:n3 ratio of the treatment diet was 5:1 compared to the 
control diet with a ratio of 11:1.  Analysis of plasma fatty acid profiles revealed 
treatment horses experienced an increase in plasma docosahexaenoic acid, along with a 
decrease in linoleic acid (C18:2n6).  Total plasma n6:n3 ratio of treatment horses was 
23:1, as opposed to 27:1 in the control horses.   
Treatment horses had significantly lower synovial fluid white blood cell 
concentration and plasma Prostaglandin E2 (P < 0.05).  A trend towards decreased 
fibrinogen (P = 0.076) was also seen in the treatment horses.  Synovial fluid TNF-α and 
IL-1 concentrations were not obtained due to problems with the assay kits or procedures. 
Force plate data from seven horses was analyzed.  No significant increase in weight 
placed on arthritic limbs (P = 0.12) was seen.  
This data provides further evidence that a decrease in the n6:n3 ratio of the diet 
and plasma can lead to a decrease in the production of inflammatory compounds in 
arthritic joints.  
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CHAPTER I 
INTRODUCTION 
1 
Arthritis is the most significant cause of lameness in horses (Todhunter et al., 
1990) and can lead to the early retirement of otherwise healthy animals.  Arthritic joints 
result from previous damage to the joint, wear and tear due to exercise, as well as the 
natural aging process.  As young animals, cartilage formation is at its highest rate and 
young horses can easily repair and replace damaged joint tissue.   However, as horses 
age, the abilities of their joints to repair themselves becomes limited.  Eventually 
cartilage metabolism becomes greater than anabolism; therefore, even small amounts of 
damage can escalate to chronic lameness (Brama et al., 2000).  Many current treatments 
for equine arthritis focus only on relieving pain and do not attempt to prevent further 
joint degradation.  In addition, some common pain-relieving treatments, such as non-
steroidal anti-inflammatory drugs (NSAIDS), can lead to other health problems when 
used continuously.  Research has shown that n3 polyunsaturated fatty acids (PUFAs) 
may safely decrease the inflammation and pain caused by arthritis, as well as possibly 
slowing the degradation of the joint (Cleland et al., 1988; Curtis et al., 2000; 
Munsterman et al., 2005).  
 Once injury or degradation of cartilage occurs in a joint, inflammation is caused 
by mediators in an attempt to stop the damage.  Numerous non-specific compounds, 
such as mast cell granules, are released to alert the body of the insult, thus initiating a 
cascade of inflammatory events starting with the infiltration of polymorphonuclear 
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leukocytes and monocytes to the site of injury.  The ultimate result is the production and 
release of inflammatory cytokines and eicosanoids from local cells.  Initially, this 
process is designed to limit use of the joint to promote healing, yet with continuous 
exercise and damage, excessive amounts of eicosanoids are released resulting in chronic 
inflammation, pain, and further degradation of the cartilage by elevated 
metalloproteinases (Palmer and Bertone, 1994).   
Examples of common inflammatory cytokines include tumor necrosis factor- α 
(TNF-α), interleukin-1 (IL-1), and interleukin6 (IL-6). These molecules have paracrine 
and autocrine properties which can further enhance their production and release.  
Cytokine release leads to the production of inflammatory eicosanoids such as 
Prostaglandin E2 (PGE2) and Leukotrienes, which are synthesized through metabolism 
of long chain PUFAs.  Arachidonic acid (AA, C20:4) is a common dietary n6 fatty acid 
which, through the cyclooxygenase and lipooxygenase pathways, is a precursor for 
PGE2 production, along with other inflammatory products such as Leukotriene B4 
(LTB4) (Calder, 2002).  Therefore, it is hypothesized that increased levels of n6 fatty 
acids in the plasma may lead to an increased production of inflammatory eicosanoids, 
enhancing the inflammatory response.  In equine, as well as human diets, n6 fatty acids 
are found in high concentrations compared to n3s. Linoleic acid (LA, C18:2n6), found 
in corn and corn oil, safflower oil, soybean oil, and AA, found in meat and animal 
products, are the most common n6 PUFAs.  Therefore the common practice of adding 
corn oil as a fat supplement for horses may actually be increasing the animal’s 
inflammatory potential.  
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Omega-3 fatty acids, such as eicosapentaenoic acid (EPA, C20:5) and 
docosahexaenoic acid (DHA, C22:6) compete with n6 fatty acids for storage in the cell 
membrane, as well as during metabolism.  When they are metabolized via the 
cyclooxygenase and lipooxygenase pathways, n3 PUFAs result in either less potent 
eicosanoids, or anti-inflammatory eicosanoids such as Prostaglandin E1, Thromboxane 
A3 and Leukotriene B5 (Calder, 2002).  Because of this difference in metabolism it is 
believed that the addition of n3 PUFAs to the diet may decrease inflammation and the 
potential pain it causes. 
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CHAPTER II 
REVIEW OF LITERATURE 
Joint Health 
 
 The degeneration of articular cartilage is the end result of osteoarthritis.  The 
main components of cartilage are collagen and proteoglycan, which are both present in 
many forms.  Collagen content is divided into various types (II, V, V, IX, XI), with type 
II occurring predominantly (Vachon et al., 1990).  Proteoglycan, formed in large 
aggregates in collagen, consists of numerous types in equine joints with each type 
having different properties and found in differing amounts depending on the horse’s 
age.  In general, proteoglycans provide high osmotic pressure in the joint and allow the 
cartilage to retain large amounts of water, cushioning the impact from flexion and load 
bearing (Maroudas et al., 1986).   Though damage to proteoglycans in the joint can be 
reversed, the collagen network has a very limited ability to repair itself, especially that 
of adult animals.  Therefore, joint damage caused by injury or age could be defined as 
permanent. 
Insult or injury to a joint results in inflammation to prevent further damage and 
promote rest and healing in the joint capsule.  Similar to the process of acute 
inflammation in other body tissues, this process leads to the release of IL-1, produced 
by the synovial lining cells and macrophages.  This acute phase activator induces the 
production of phospholipase A2 which releases fatty acids from cellular phospholipids.  
These fatty acids are then metabolized through the cyclooxygenase and lipooxygenase 
pathways resulting in the production of eicosanoids, such as inflammatory PGE2 (Pujol 
and Loyou, 1987).  Interleukin-1 can also lead to the synthesis of metallproteoglycanase 
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and collagenase in chondrocytes.  These enzymes are known to degrade the collage 
matrix (Mizel, 1989).  Though the inflammatory process is designed to promote healing 
of the tissue, continuous use and damage results in the constant production of IL-1 and 
the resultant joint-damaging compounds.   
 As noted previously, the precursor to inflammatory eicosanoids such as PGE2 is 
arachidonic acid (AA).  As the AA (C20:4) content of membranes increases, the ability 
of cells such as chondrocytes and synovial cells to produce inflammatory products is 
enhanced.  With increasing severity of histological damage to human joints, an increase 
in lipid accumulation in the articular cartilage was noted by Lippiello et al. (1991).  
Specifically, AA levels increased 393% and 1,150% in mild and severe cases of joint 
injury, respectively.  This suggests free fatty acids are involved in the initial response 
during the development of joint disease.  Biochemically, n3 PUFAs are known to 
compete with n6s for storage in the cell, release from the cell membrane, and 
metabolism.  The concentration of n3s in the cell membrane is dependent upon n3 
consumption by the animal.  An increase in intake will lead to increased n3s and 
decreased n6s in the cell.  A subsequent increase in the rate of release from the cell 
membrane by Phospholipase A2 and further n3 metabolism will then occur.  In addition, 
products from the metabolism of n3s, such as Prostaglandin E3, are less inflammatory 
than those from n6s.  Therefore, a higher intake of n3s, leading to increased levels of 
n3s in the membrane and a resultant decline in membrane n6s, can decrease the ability 
of cells to produce inflammatory products after insult to a joint (Calder, 2002). It has 
also been suggested that n3s can decrease production of inflammatory cytokines at the 
level of gene expression by way of signal transduction (Calder, 2002). 
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Various treatments are available for the management of osteoarthritis in horses.  
Non-steroidal anti-inflammatory drugs (NSAIDS) such as phenylbutazone are utilized 
for pain management. However, continuous usage of NSAIDS at high doses can lead to 
other health problems such as stomach ulcers (MacAllister et al., 1993).  Recently, oral 
supplements containing glucosamine and/or chondroitin sulfate have become very 
popular; however, research has yet to verify their efficacy.  Both compounds are 
required for the repair and maintenance of joints, and ideally consuming additional 
amounts of one or both compounds will provide an excess of resources required to 
maintain a healthy joint.  Research has focused on how effective these compounds are in 
repairing joints when consumed orally.  The bioavailability of chondroitin sulfate in 
equines has been estimated at 13.2% of the amount ingested (Conte et al., 1991).  This 
percentage is then available in the bloodstream for incorporation into tissues, such as 
cartilage.  However, even if available in the plasma, both chondroitin sulfate and 
glucosamine can be filtered out of the blood after one pass through the liver further 
decreasing their usefulness in the body. 
Numerous studies investigating the effects of oral supplements have found 
beneficial results, however, some researchers question the validity of these results.  
McAlindon et al. (2000) performed a meta-analysis and quality assessment of 15 
clinical trials testing the efficacy of oral chondroitin sulfate and glucosamine 
supplements as treatments for arthritis in horses.  Most individual trials demonstrated 
moderate positive effects; however, they observed major deficiencies in randomization, 
blinding and completion rates in trials. Therefore, these positive results may not be 
trustworthy and alternative treatments need to be explored. 
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Omega-3 Fatty Acids 
Numerous in vivo and in vitro studies have investigated the anti-inflammatory 
effects of n3 PUFAs in horses, mice, and humans.  Curtis et al. (2000) used bovine 
cartilage in vitro to study the effect of increasing levels of n3s in the membrane of IL-1 
stimulated chondrocytes. Higher levels of n3s in the cell membranes resulted in a dose-
dependent reduction in the expression of TNF-α and IL-1, as well as a decrease in the 
expression of proteoglycan-degrading enzymes such as aggrecanase.  Stride length was 
used by Woodward et al. (2005) to measure lameness in arthritic horses fed 
supplemental EPA (C20:5) and DHA (C22:6).  A trend towards greater trot stride length 
was observed in horses consuming 15 g of supplemental EPA and DHA per day, 
indicating a reduction in lameness.  These results provide evidence that n3 PUFA 
supplementation may be beneficial to the arthritic joint.  
Research has also been conducted to evaluate n3 supplementation in the 
formation of inflammatory markers in other animals.  Eicosanoid production was 
stimulated in healthy mice consuming varying levels of n6 and n3 fatty acids (Li et al., 
1994).  Pooled eicosanoid production was lower in mice consuming additional EPA.  It 
was also noted that mice consuming supplemental EPA (C20:5n3) and AA (C20:4n6) 
had similar eicosanoid production as mice consuming only AA.  Due to these results the 
authors illustrated the importance of feeding only one type of fatty acid per treatment 
group due to a suppressive effect of AA on EPA metabolism.  Song et al. (2003) 
observed a similar response when feeding Wistar rats ethyl-EPA and using IL-1 to 
induce stress and inflammation.  Consumption of ethyl-EPA reduced the elevated PGE2 
secretion and increased secretion of the anti-inflammatory cytokine Interleukin-10.  
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Treatment with EPA also significantly blocked the elevation of corticosterone released 
in response to anxiety.  Therefore, elevated intakes of EPA versus AA may be effective 
at decreasing the production of inflammatory markers such as eicosanoids and 
cytokines. 
 A large amount of n3 research has also been conducted in humans with 
rheumatoid arthritis (RA).  In one study, patients with RA consumed 3.2 g EPA (C20:5) 
and 2.0 g DHA (C22:6) daily compared to the control group which consumed 1g olive 
oil daily, which is believed to contain neutral fatty acids, for 12 weeks.  Tender joint 
score and grip strength were improved in the treatment group, along with a decreased 
production of LTB4 by isolated neutrophils (Cleland et al., 1988). A study conducted by 
Kremer et al. (1990) resulted in a 54.7% decrease in macrophage IL-1 and a 20.0% 
decrease in neutrophil leukotriene B4 (LTB4) in a group of RA patients receiving 54 
mg/kg of EPA and 36 mg/kg of DHA for 24 weeks.  Patients also experienced a 
significant reduction in tender and swollen joints. Lau et al. (1993) reported similar 
results in patients with RA.  Patients consuming fish oil, which naturally contains high 
amounts of EPA and DHA, were able to significantly reduce their level of RA 
medication (NSAIDS) without an increase in pain or other symptoms.  
In addition, Adam et al. (2003) noted patients that consumed an anti-
inflammatory diet containing less than 90 mg/day of AA showed significantly lower 
formation of LTB4 and prostaglandin metabolites, compared to patients consuming a 
typical diet.  In addition, by simply reducing the intake of AA (C20:4n6), patients had a 
higher enrichment of EPA (C20:5n3) in erythrocyte lipids.  When fish oil was included 
in the low AA diet, the anti-inflammatory benefits indicated above were even greater.  
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These studies provide evidence that decreasing consumption of n6s alone can reduce 
problems associated with joint disease.  
Measuring Joint Health 
It is difficult to objectively determine the presence and extent of joint disease in 
animals.  It is suggested that levels of inflammatory cytokines and eicosanoids in blood 
and synovial fluid could be used as markers of arthritis.  Though blood samples are 
easier to obtain, concentrations of these compounds in synovial fluid have been shown 
to be more indicative of joint disease.  Serum or plasma concentrations reflect the 
condition of the entire body, rather than just diseased joints.  Many joint markers may 
also be eliminated by the time they reach the vascular system.  Eicosanoid and cytokine 
concentrations are also much higher in the synovial fluid and therefore should be easier 
to detect and monitor (Lohmander et al., 1992).  Synovial fluid white blood cell (WBC) 
count is commonly used to identify joint problems, and the concentration in normal 
equine joints has been reported as 167 + 21 cells/ml and 76 + 99 cells/ml, respectively 
(Van Pelt, 1974; Persson, 1971).  However, it is also noted in traumatic arthritis and 
osteoarthritis that the cell count may vary tremendously (McIlwraith et al., 2001).  
Little research has been done to determine a normal concentration range for 
many eicosanoids or cytokines in equine plasma and synovial fluid.  However, Bertone 
et al. (2001) conducted a study to verify the sensitivities of many compounds and their 
ability to predict joint disease and changes in joint health.  Synovial fluid prostaglandin 
E2 and IL-6 were found to be excellent predictors of joint disease in horses, while TNF-
α and IL-1 were no more effective than a white blood cell count.  In addition, Kirker-
Head et al. (2000) found PGE2 concentrations were increased in equine osteoarthritic 
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joints compared with normal joints.  However, Bertone et al. (2001) also noted PGE2 
concentration was highly variable among horses. In addition, though synovial fluid 
PGE2 is a very sensitive marker, and therefore able to detect minor problems, the 
magnitude of its production and release does not appear to be well correlated to the 
degree of insult.  A minor insult can result in PGE2 concentrations similar to those after 
a major insult in the same horse.  Synovial fluid IL-1 and TNF-α are not as sensitive to 
small insults; however, they are less variable between horses and concentrations are 
more strongly correlated to the magnitude of insult (Bertone et al., 2001).  This 
characteristic may make them better suited to monitor minor changes in cartilage and 
joint health such as those expected from horses with chronic osteoarthritis. 
Fibrinogen is an acute-phase protein produced by the liver in response to 
inflammation. It plays an important role in the inflammatory process by acting as the 
substrate for thrombin in the clotting cascade.  Plasma fibrinogen concentrations are 
believed by some practitioners to be important in identifying inflammatory diseases 
(Andrews et al., 1994).  Due to its presence in the blood, fibrinogen concentrations 
cannot indicate the specific location of the insult or injury.  However, similar to other 
inflammatory compounds in the plasma like PGE2, changes in the fibrinogen 
concentration can be used to indicate a change in the inflammatory status of an animal. 
Beneficial Levels of Omega-3s  
In order for n3s to have beneficial effects they must be present in the circulation 
and incorporated into tissues.  Previously, researchers have supplemented the common 
n3 PUFA alpha-linolenic acid (ALA, C18:3) to evaluate the anti-inflammatory 
properties of long chain fatty acids.  However, ALA must be converted into EPA 
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(C20:5) and then DHA (C22:6) by a desaturase enzyme before it can be useful to the 
animal. The conversion rate of ALA to EPA can vary between 0.2% and 21%, while the 
conversion of ALA to DHA varies between 0% and 9% (Burdge, 2004).  Therefore it 
may be more effective to directly feed EPA and DHA, which are found in large amounts 
in fish and fish products, rather than products high in ALA such as flaxseed. 
O’Connor et al. (2001) supplemented equine diets with fish oil containing 10.8% 
EPA (C20:5n3) and 8% DHA (C22:6n3), resulting in a 4.8 fold increase in plasma EPA 
and a 4.66 fold increase in plasma DHA after 63 days. Additionally, King et al. (2005) 
reported a significant increase in both plasma EPA and DHA after feeding an n3 
supplement for 28 days. As determined through previous studies, a level of 3.2% plasma 
phospholipid EPA and DHA must be reached in order to be effective at suppressing 
inflammatory cytokines and eicosanoids (Cleland et al., 2003).  This concentration has 
been found in numerous studies in which beneficial results were obtained.  Based on 
research completed in this laboratory (Ross, 2006), horses consuming 15 g of EPA and 
20 g of DHA daily will reach this required percentage. 
Numerous studies have provided evidence that n3 PUFA supplementation may 
be effective at reducing inflammation associated with diseases such as arthritis.  
However, while some research has shown benefits involving subjective measures of 
joint disease, none has evaluated the concentrations of inflammatory markers in 
synovial fluid of arthritic joints. To fully support the theory that n3 PUFAs are 
beneficial in the arthritic joint, it is necessary to monitor changes within the joint during 
supplementation. 
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CHAPTER III 
MATERIALS AND METHODS 
Horses 
Sixteen mature arthritic horses, of Quarter Horse and Thoroughbred breeding, 
were blocked by severity of arthritis, affected joints, and age, and randomly divided into 
two groups. Severity of arthritis was determined by radiographs, lameness as 
determined by weight distribution measured by force plates, and d 0 synovial fluid 
WBC concentration.  In total the study observed twenty knees, five fetlocks, one stifle, 
and two hock joints from ten geldings and six mares with a mean age of seventeen 
(Table 1). 
 
Table 1.  Summary of joints observed in osteoarthritic horses with and without n3 
PUFA supplementation.  
Joint Control Treatment Total observed 
Number of horses 
observed 
Knee 10 10 20 10 
Fetlock 3 2 5 4 
Stifle 1 0 1 1 
Hock 0 2 2 1 
 
 
 
Horses were housed in 10m x 20m dry lot pens at the Texas A&M University 
Horse Center.   Routine farrier work, vaccinations and de-worming were consistent with 
farm protocols.  Body weight was measured every 30 days to adjust feed intake as 
needed.  All protocol for this study were within the guidelines set forth by the 
Institutional Agricultural Animal Care and Use Committee (AUP# 2006-85). 
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Diets 
 One group of horses (n = 8) was randomly designated to the control diet; the 
second group (n = 8) was assigned to the treatment diet.  Horses received their 
respective dietary treatments for 90 days.  Diets were fed at levels to maintain an 
optimal body condition score (BCS= 5-6).  The control group received a 12% crude 
protein textured feed purchased from Producer’s Cooperative Association, Bryan, 
Texas, at 1% BW per day. Treatment horses received the same mixed feed and two 
pelleted n3 supplements (JBS United Feeds Inc, Sheridan, Indiana).  In order to 
maintain isocaloric treatment groups, the treatment horses consumed 0.86 kg less than 
1% of BW in concentrate (Table 2).  As seen in the Results section, analysis revealed 
the gross energy supplied by the treatment and control diets was statistically equal (P < 
0.05).   Supplement A was formulated to contain EPA and DHA at 2.8% of total fatty 
acids, and supplement B was formulated to contain 2.2% EPA and 3.8% DHA.  Each 
treatment horse received 300 g of each supplement per day, supplying an additional 15 g 
EPA (C20:5n3) and 19.8 g DHA (C22:6n3) to the diet.   
Horses were placed in individual stalls and fed the concentrate or 
concentrate/supplement ration in twice daily at 12-hour intervals.  Concentrate and 
supplements were weighed out prior to each feeding, and supplements were mixed into 
the concentrate immediately before consumption.  Intakes and refusals were measured 
daily, and all horses consumed 2.01 kg/hd/d of concentrate on average.  Both diets 
included group-fed access to coastal hay at approximately 1.3% BW, and horses 
consumed approximately 6.12 kg/hd/d.  Grain, hay, and supplements were sampled 
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randomly throughout the study and analyzed for n3 and n6 PUFA concentration (Tables 
on pages 22 and 23) and gross energy concentrations.  
 
Table 2. Mean total daily intake in osteoarthritic horses with and without n3 PUFA 
supplementation (kg/hd/d). 
Group Concentratec Coastal Hay Supplement Ad Supplement Be
Control 4.60a 6.12 -- -- 
Treatment 3.40b 6.12 0.3 0.3 
a,b  Values within columns lacking common superscripts differ by P < 0.01 
c   Textured feed containing 12% crude protein 
d n3 supplement containing 2.8% EPA and DHA 
e n3 supplement containing 2.2% EPA and 3.8% DHA 
 
 
Sample Collection 
Fasting blood samples were collected prior to the morning feeding on d 0 and at 
14-day intervals for the remainder of the study via jugular veni-puncture. Plasma 
samples were collected into triplicate 5 ml evacuated tubes containing EDTA, and into a 
single 5 ml evacuated tube containing lithium heparin.  On d 0, serum samples were 
collected into a single 10 ml evacuated tube without additives. Samples collected in 
heparin tubes were stored in a cooler at 4oC for immediate fibrinogen analysis. All other 
samples collected were cooled on ice and centrifuged at 3200 rpm for 20 minutes.  After 
separation, plasma and serum were pipetted into labeled 1.5 ml microcentrifuge tubes, 
where they were capped and stored upright at -20 oC.  Prior to freezing, the PGE2 
inhibitor indomethacin was added at 10% of volume to the EDTA samples to be used 
for PGE2 analysis.  
Synovial fluid was collected from each horse, from at least one affected joint, on 
d 0, 30, 60, and 90.  Joints were washed with a Betadine and water mix prior to 
arthrocentesis.  All fluid was collected in 3 ml evacuated tubes containing EDTA and 
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immediately cooled on ice.  Samples for cytokine analysis were centrifuged at 3200 rpm 
for 20 minutes, pipetted into microcentrifuge tubes and stored upright at -20 oC for later 
analysis.  Samples used to determine synovial fluid WBC concentration were 
immediately cooled on ice and taken to the Texas Veterinary Medical Diagnostic Lab, 
College Station, TX, for analysis on a Celdyne 3700 cell counter. 
Force plate analysis was conducted on d 0, 30, 60, and 90 to determine changes 
in weight distribution throughout the study according to procedures described by Hood 
et al. (2001).  Four independent force plates (weight scales), one for each foot, were 
connected to a custom-designed computer system in a set of stocks.  This system 
records the mean load, calculated as a percent of body weight, placed on each foot every 
0.1 s over a 3 min period (Hood et al., 2001).  Three readings were taken for each horse 
on each day.  All horses were trailered to the force plates on the mornings of collection 
days prior to arthrocentesis to avoid discrepancies in lameness due to the procedure. 
Laboratory Analysis    
Dry matter content of concentrate and forage samples was determined.  Feed 
samples were ground using a Wiley mill accommodated with a 1 mm mesh screen.  
Approximately 2.0 g of ground concentrate and forage sample were measured in 
triplicate into aluminum pans and placed in a drying oven (68°C) for 72 hours.  Pans 
were removed and placed inside a dessicator for cooling and to prevent condensation. 
Sample analysis was repeated if standard error was greater than 5%.  Dry sample weight 
was determined by subtracting sample weight after drying from the sample weight prior 
to drying.  Dry matter percentage was calculated using the following formula: 
   
 
 
   
16
 
Dry sample weight (g) 
                                       X 100 
  Wet sample weight (g) 
 
 Plasma fibrinogen concentration was determined within 24 h of blood collection. 
Fibrinogen concentration was determined using micro-hematocrit heat precipitation 
methods of Millar et al. (1971).  Whole blood was harvested into collection tubes 
containing heparin. Two 75 mm heparinized micro-hematocrit capillary tubes (Fisher 
Scientific) were filled at least 50% with whole blood and sealed at one end using 
critoseal (Oxford Labware).  The tubes were centrifuged for 5 minutes, then 
immediately transferred upright into a water bath (56 +/-1°C) for 3 min, and centrifuged 
for an additional 3 min.  Using a digital caliper, the length of the fibrinogen column and 
total length of fibrinogen-plasma column was measured.  Fibrinogen concentration 
(mg/dl) of each sample was determined using the following equation: 
   Fibrinogen column 
          X 10,000 
   Fibrinogen-plasma column 
  
Plasma, serum, supplement, concentrate, and forage samples were analyzed for 
total fatty acid concentrations using a gas chromatograph (GC).  All feed samples were 
dried prior fatty acid analysis, and 50-500 mg of dried samples were placed in screw cap 
tubes with Teflon lined caps.  Two ml of benzene containing the internal standard, 
methyl tridecanoic acid (C13:0), was added to all tubes, along with 3 ml of methanolic-
HCl.  Nitrogen (N2) gas was added, and samples were capped and vortexed.  Tubes 
were then heated for 2 hr in an 80°C water bath.  After heating, tubes were cooled to 
room temperature and 5 ml of 6% K2CO3 and 2 ml benzene was added; tubes were 
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vortexed.    Tubes were then centrifuged at 500 rpm for 5 min.  The upper organic 
solvent layer was then transferred to a GC vial.  The autosampler obtained 1.0 µl of 
sample for analysis in the Supelco SP-2560 capillary column.  Temperature at injection 
and detection was 260°C, and column flow rate was 1.1 ml/min.  The Supelco 37 
FAME mix (# 47885-U) was used as a standard. 
 Plasma was pipetted in 500 µl units in to 15 ml screw cap tubes for fatty acid 
analysis.  Samples were freeze-dried overnight prior to analysis.  One ml of benzene 
containing the internal standard (1000µg/ml methyl-C:13) was added and tubes were 
capped and vortexed.  Four ml of Supelco B252, the BF3-Methanol reagent, was added 
and tubes were gently mixed.  Tubes were then tightly capped and incubated for 60 min 
at 60°C.  After tubes cooled to room temperature, 4 ml of double distilled H20 and 1 ml 
hexane was added.  Tubes were vigorously mixed and centrifuged at 1000 rpm for 5 
min.  The upper solvent layer, approximately 1-2 ml, was transferred to a GC vial and 3-
4 small crystals of anhydrous sodium sulfate were added to remove small amounts of 
water that may have remained in the sample.  Fatty acid analysis of plasma was 
conducted using the same GC column and procedures used for feed analysis. 
Gross energy content was determined on ground samples of concentrate, hay, 
and supplements.  Samples were not dried before analysis.  Approximately 1.0 g 
aliquots of concentrate and hay, and 0.5 g aliquots of supplement A and supplement B 
were measured.  Gross energy was then determined on the aliquots by bomb 
calorimetery using a Par 6300 oxygen-bomb calorimeter (Parr Instrument CO., Moline, 
IL).   
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Plasma samples were analyzed for PGE2 using enzyme-linked immunoassay 
(ELISA) kits (R&D systems, Minneapolis, MN).   Plasma samples required 2, 5 and 10-
fold dilutions depending on the severity of arthritis.  The mean minimum detectable 
dose of PGE2 was 27.5 pg/ml.  Dilutions were made with a calibrator diluent provided 
by the kit prior to beginning the assay.   
Synovial fluid IL-1 and TNF-alpha were determined using ELISA kits 
(Amersham Biosciences, Piscataway, NJ). Samples for IL-1 analysis required 2-fold 
dilutions, and samples analyzed for TNF-alpha required 5-fold dilutions.  The mean 
minimum detectable dose was 0.1 pg/ml for both kits. Dilutions were made with a 
calibrator diluent provided by the kit prior to beginning the assay.   
ELISA kits supplied all necessary reagents, and concentrations were read using a 
Biotek microplate reader (Biotek Instruments, Inc., Winooksi, VT)at 450nm. All assay 
samples, standards, and controls were run in duplicate unless otherwise stated and were 
repeated if the standard error was greater than 5%. 
Statistical Analysis 
 All data was analyzed by analysis of variance (ANOVA) using STATA 8 
statistical software (Stata Corp., College Station, TX).  Due to the high variability 
between horses and large variation between groups at day 0, normalized values were 
compared by subtracting day 0 values from all measurements.  Each parameter was 
analyzed for treatment, day, and treatment by day interactions.  
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CHAPTER IV 
RESULTS 
Horses 
One horse from the control group was euthanized on d 60 due to problems 
unrelated to the study. The horse entered the study with laminitis, however, after d 30 
the severity of the laminitis worsened. This increase in inflammation of the tissue in the 
foot increased plasma fibrinogen and PGE2 beyond the range associated with normal 
variation.  For this reason, all plasma data for this horse were removed.  In addition, the 
laminitis affected the front limb opposite of that in which synovial fluid was obtained.  
Therefore, more weight was placed on the observed knee joint exposing the joint to 
conditions vastly different from those on d 0.  Data from synovial fluid analysis were 
also removed. 
Partial data from one horse in the treatment group were also removed from the 
study due to a worsening in laminitis.  All plasma values were dropped; however, 
synovial fluid WBC concentration did not appear to be greatly affected, compared to d 0 
values, so this data was kept.  
Diet Analysis 
The coastal hay contained more gross energy than expected (Table 3); however, 
each horse in the study was consuming similar amounts and therefore this difference 
was not a factor.  Diets were formulated to be isocaloric, and the control horses were 
consuming 43.57 Mcal/hd/d compared to 41.77 Mcal/hd/day for the treatment group 
(Table 3).  This difference is not significant (P < 0.05).  
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Table 3.  Gross energy content of diet components (Mcal/kg) and daily mean gross 
energy intake (Mcal/hd/d) of osteoarthritic horses with and without n3 PUFA 
supplementation.   
Component Gross energy Controla Treatmenta 
Concentrate 4.05 18.63 13.77  
Coastal Hay 4.08 24.94 24.94 
Supplement A 5.07 ---   1.52 
Supplement B 5.13 ---   1.54 
Total  43.57 41.77 
a Calculated by multiplying average daily intake and gross energy content of diet component. 
 
Fatty acid concentrations in feeds are typically reported as a percent of total fatty 
acid content.  However, it is also necessary to determine the actual amount of each fatty 
acid consumed by the horse to use in subsequent research or diet formulations.  In order 
to do this, fatty acid profiles must be determined as a percent of the total diet.  Tables 4 
and 5 report the fatty acids in both forms.  
Coastal hay was analyzed for fatty acid profile, and all results can be found in 
appendices 1 and 2.  Hay was group-fed and all horses were offered similar amounts, 
therefore the fatty acids supplied by the hay do not differ between control and treatment 
groups. 
As shown in Table 4, linoleic acid (C18:2n6) and alpha-linolenic acid (C18:3n3) 
were found in high concentrations in the concentrate, specifically 42.107% linoleic acid 
and 3.496% alpha-linolenic acid as a percent of total fatty acids.  These results agree 
with previous research in our lab (Ross, 2006).  Eicosapentaenoic acid (C20:5n3) was 
found in lower concentrations than expected in the supplements.  It was found to be 
0.096% and 0.066% of supplement A and B, respectively, while we were anticipating 
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levels closer to 2.5%.  Concentrations of DHA (C22:6n3) are also slightly lower than 
expected, though not as low as EPA. 
While the EPA concentration in the supplements was much lower than expected, 
the total n6:n3 ratios of both supplements are still lower than n3 sources used in other 
studies due to moderate DHA concentrations.  Previous studies have fed oils or 
supplements at 6:1 or 5:1 n6:n3 ratio (Ross, 2006), while the supplements used in this 
research had ratios of 1.2:1 and 0.4:1 in A and B, respectively (Table 4).   
 
 
 
Table 4.  Fatty acid profile of concentrate and n3 supplements, reported as % of total 
fatty acids (% by weight). 
Fatty acid Concentrate Supp. A Supp. B 
C18:2n6 (LA) 42.107 5.502 7.407 
    
C18:3n6 (GLA) 0.001 0.002 0.004 
    
C18:3n3 (ALA) 3.496 1.152 2.241 
    
C20:3n6 (DGLA) 0.017 0.135 0.210 
    
C20:4n6 (AA) 0.030 0.325 0.717 
    
C20:5n3 (EPA) 0.113 0.096 0.066 
    
C22:5n3 (DPA) 0.020 0.025 0.027 
    
C22:6n3 (DHA) 0.165 3.732 17.931 
    
n6:n3 ratio 11.0:1 1.2:1 0.4:1 
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Table 5. Fatty acid profile of concentrate and n3 supplements, reported as actual % 
of each diet component. 
Fatty acid Concentrate Supp. A Supp. B 
C18:2n6 (LA) 2.430 0.575 1.075 
    
C18:3n6 (GLA) 0.003 0.016 0.052 
    
C18:3n3 (ALA) 0.202 0.121 0.325 
    
C20:3n6 (DGLA) 0.001 0.014 0.031 
    
C20:4n6 (AA) 0.002 0.034 0.104 
    
C20:5n3 (EPA) 0.007 0.010 0.019 
    
C22:5n3 (DPA) 0.001 0.003 0.004 
    
C22:6n3 (DHA) 0.009 0.389 2.600 
    
 
 
Intake of all fatty acids except EPA (C20:5n3) were different between groups (P 
< 0.05) (Table 6).  This was due not only to the inclusion of supplements in the 
treatment diet, but also due to the increased concentrate in the control diet to maintain 
isocaloric diets.  As expected, increases in grain intake in the control group resulted in a 
higher LA (C18:2n6) intake due to the higher concentration of this component.  In 
addition, the amount of DHA (C22:6n3) consumed was much higher in the treatment 
group than the control.   All other fatty acids were consumed in similar amounts when 
evaluated from a physiological perspective.  
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Table 6.  Fatty acid consumption (g) of osteoarthritic horses with and without n3 PUFA 
supplementation, excluding those supplied by hay. 
Group  
LA 
18:2 n6 
GLA 
18:3 n6 
ALA 
18:3 n3 
DGLA 
20:3n6 
AA 
20:4 n6 
EPA 
20:5 n3 
DPA 
22:5 n3 
DHA 
22:6 n3 
Control 113.69 a 0.14 a 9.36a 0.05a 0.09 a 0.33 0.05c 0.42 a 
Treatment   88.24 b 0.31 b 8.18 b 0.17 b 0.46 b 0.32 0.06 d 9.28 b 
a,b  Values within columns lacking common superscripts differ by P < 0.01 
c,d Values within columns lacking common superscripts differ by P < 0.05 
 
 
 
When n6:n3 ratios were compared, decreased LA (C18:2n6) and increased DHA 
(C22:6n3) intakes of horses in the treatment group vastly affected the n6:n3 ratios 
(Table 7).  
 
 
Table 7.  Total n6 and n3 fatty acids consumed (g), and n6:n3 ratios, of osteoarthritic 
horses with and without n3 PUFA supplementation, excluding those supplied by hay.  
 n6s consumed n3s consumed n6:n3 ratio 
Control 114.00a  10.20 a 11.0:1 
Treatment    89.20 b  17.80 b   5.0: 1 
a,b Values within columns lacking common superscripts differ P < 0.01   
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Plasma Fatty Acid Profiles 
Mean plasma fatty acid concentrations are found in Table 8.  Treatment horses 
had higher mean plasma concentrations of DHA (C22:6n3) and decreased 
concentrations of LA (C18:2n6) (P < 0.05).  Linoleic acid concentrations were also 
lower on d 15, 60, and 90 in treatment horses (P < 0.05).  Docosahexaenoic acid 
concentrations were significantly higher in treatment horses on all days except 0 and 75 
(P < 0.05).   
In addition, plasma AA (C20:4n6) was greater in the treatment horses, and EPA 
(C22:5n3) was decreased compared to control (P < 0.05). While mean ALA (C18:3n3) 
concentrations were not different between groups, treatment horses did have lower 
concentrations on d 45, 60, and 90. 
 The decreased LA (C18:2n6) concentration was mainly due to decreased 
concentrate intake of treatment horses.  This reduction in n6 fatty acid intake plays a 
large role in decreasing the plasma n6:n3 ratio seen (Table 9).  As noted above, the 
lowered n6:n3 ratio of the treatment diet was due in part to an increased DHA 
(C22:6n3) concentration. This was also reflected in the plasma values (Table 8).  
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Table 8. Mean plasma fatty acid concentration (µg/g) of osteoarthritic horses with and 
without n3 PUFA supplementation.   
 d 0 d 15 d 30 d 45 d 60 d 75 d 90 Mean 
C18:2n6 (LA)               
Control 821 796a 768 759 749a 724 768a 769a 
Treatment 892 681b 647 635 591b 616 628b 670b 
         
C18:3n6 (GLA)        
Control 5.6 4.4 3.7 2.9 3.7 3.6 5.5 4.2 
Treatment 5.2 5.6 4.8 2.4 4.2 2.9 2.9 0.3 
         
C18:3n3 (ALA)        
Control 36.3 19.5 17.6 16.6a 16.9a 12.4 17.9a 19.6 
Treatment 36.6 13.8 13.1 13.1b 11.9b 11.5 12.8b 16.1 
         
C20:3n6 (DGLA)        
Control 7.0 7.1a 4.5 6.1 5.9 6.4 8.4 6.5 
Treatment 5.9 5.7b 5.4 6.6 6.3 6.6 7.0 6.2 
         
C20:4n6 (AA)               
Control 1.7 1.4a 1.5a 2.4 1.7a 1.6 1.6 1.7a 
Treatment 1.9 3.6b 3.2b 3.4 3.4b 3.0 4.2 3.2b 
         
C20:5n3 (EPA)               
Control 2.7 3.0a 1.9 2.0 2.1 1.9 2.4 2.3a 
Treatment 1.7 1.1b 1.5 1.3 1.9 1.0 1.0 1.4b 
         
C22:5n3 (DPA)               
Control 2.9 2.5 2.5 3.1 2.5 2.8 2.6 2.7 
Treatment 4.2 2.3 3.4 2.0 3.3 2.7 3.5 3.0 
         
C22:6n3 (DHA)               
Control 5.2 4.6a 3.4a 4.1a 2.8a 2.4 2.0a 3.5a 
Treatment 5.1 7.9b 10.3b 10.0b 7.9b 7.9 7.8b 8.4b 
         
a,b Values within columns within the same fatty acid lacking common superscripts differ by P < 0.05
  
 
Total n3 concentration in the plasma was not different between groups (Table 9). 
A decreased n6:n3 ratio in the plasma was due to a decrease in mean plasma n6 
concentration (P < 0.05).  
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Table 9.  Plasma concentration (µg/g) of total n6 and n3 fatty acids of osteoarthritic 
horses with and without n3 PUFA supplementation.   
 n6     n3   
Day Control Treatment  Day Control Treatment 
0 835  905  0 47.1 47.5 
15 809a   696b  15 29.6 26.8 
30 778  661  30 25.5 28.3 
45 771 647  45 25.8 26.4 
60 760a   605b  60 24.4 25.0 
75 735 629  75 19.6 23.1 
90 784a   642b  90 24.9 25.2 
Mean 782a  683b  Mean 28.1 28.9 
n6:n3 ratio 27:1  23:1     
a,b Values within rows lacking common superscripts differ by P < 0.05 
 
Synovial Fluid WBC Concentration 
A treatment effect on synovial fluid WBC concentration was observed when the 
data were normalized.  Horses consuming n3 supplements experienced a significantly 
larger negative change in WBC concentration (P < 0.05) compared to control horses.  
Treatment horses experienced a change of -214 + 55 cells/ml compared to 90 + 144 
cells/ml in the control group for the entire trial. 
Horses consuming the control diet had increased WBC concentration on d 30; 
however, the concentration returns to near d 0 values by the next data collection at d 60 
(Figure 1).  The lack of a pre-trial adjustment period for all horses and abrupt changes in 
living conditions and diet could explain the increase in WBC concentration within the 
first 30 days.  The concentration of synovial fluid WBC concentration is observed to 
decline consistently throughout the 90 d trial. 
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Figure 1.  Mean change in synovial fluid WBC concentration in osteoarthritic horses 
with and without n3 PUFA supplementation.   
 
 
Plasma PGE2 
There was a similar treatment effect on plasma PGE2 concentrations with the 
treatment horses exhibiting a significantly larger negative change (P < 0.05) in plasma 
PGE2 than the control horses.  Mean plasma PGE2 in the control horses increased by 540 
+ 278 pg/ml, while the treatment horses experienced a mean change of -420 + 247 
pg/ml. 
As illustrated in Figure 2, plasma PGE2 concentrations of both groups separated 
from d 0 until d 30 at which point they parallelled each other from d 30 through d 90.  
The treatment group experienced a lower mean concentration throughout.  The 
separation of means in the beginning of the study could have been due the time 
necessary for accumulation of fatty acids in to the tissue, as well as acclimation to the 
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study environment.  After d 30, it appears concentrations level out, with both groups 
experiencing similar variations in mean concentration. The cause of increased mean 
concentrations between d 75 and 90 is unclear.  Both groups experienced a similar 
increase, but while no significant differences on individual days are seen due to high 
variability, the treatment horses appear to experience a smaller increase in 
inflammation.  The PGE2 concentration in the plasma of control horses increased twice 
as much as the treatment group from d 75 to d 90 (Appendix 9). 
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Figure 2.  Mean change in plasma PGE2 concentration in osteoarthritic horses with and 
without n3 PUFA supplementation.   
 
 
Plasma Fibrinogen 
Plasma fibrinogen was also measured at 15-day intervals throughout the study, 
beginning at d 0.  A trend (P = 0.076) towards a larger negative change in plasma 
fibrinogen concentrations was observed in the treatment horses compared to the control 
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horses.  Mean change in the control group for the entire trial was  -9.5 + 10.5 mg/dl 
compared to -40 + 13.3 mg/dl in treatment horses. 
Due to an increase in fibrinogen concentration for both groups on d 15 (Figure 
3), data were also analyzed from d 30 to d 90.  In removing d 0 and d 15, analysis 
revealed concentrations between groups were significantly different (P< 0.05).  After d 
30, fibrinogen in both groups decreases with the control lowering to near d 0 values and 
the treatment horses experiencing a much larger negative change.  Analogous to plasma 
PGE2, following the separation of mean concentrations the concentrations in both 
groups follow the same pattern. 
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Figure 3.  Mean change in plasma fibrinogen concentration in osteoarthritic horses with 
and without n3 PUFA supplementation.  
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Synovial Fluid Interleukin-1 and Tumor Necrosis Factor-α 
 Synovial fluid cytokine concentrations were not obtained due to difficulties with 
the assay kits or procedures.  Numerous kits were used for both assays, as well as a 
variety of dilutions, including 1:10, 1:5, 1:2, and no dilution.  Kits were stored at 4oC 
immediately upon arrival until use (within 4 wks).  No data were ever obtained for 
TNF-α kits.  Regardless of the dilution, the plate reader was unable to determine any 
changes in concentration.  All readings were below the lowest point on the standard 
curve.  The assays for IL-1 resulted in approximately half of the data points assayed for; 
however, these data points were later determined to be unusable.  Similar to TNF-α, the 
concentrations were found to be very low regardless of the dilution used.  Though little 
previous research has been done to verify normal IL-1 concentrations in equine synovial 
fluid, the values obtained were much lower than concentrations seen in normal or 
arthritic joints.  Even those data points that could be duplicated appeared random and 
unrelated to other values obtained for the same horse on different days.  Assay kit 
directions were followed closely, and kits were used within the recommended time 
frame.  In addition, no synovial fluid was frozen and thawed more than once.  Fluid was 
analyzed within 6 mo of collection.  However, synovial fluid was not flash frozen in 
liquid nitrogen immediately upon collection, which is one difference compared other 
studies in which equine synovial fluid was assayed (Bertone et al., 2001).  Instead, as 
mentioned previously, fluid was centrifuged, pipetted off, and frozen at -20 oC within 
one hour of collection.  This variation may account for the lack of useable values 
obtained by the assay kits. 
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Force Plate Analysis 
 In measuring changes in weight distribution by force plate analysis no 
significant difference was seen between groups.  Most horses on the project had arthritis 
in more than one joint, or unrelated lameness issues in the leg opposing the joint 
observed by arthrocentesis.  Two horses were affected by laminitis in the opposite foot, 
and numerous others had moderate to severe arthritis in multiple joints in the same limb 
or the limb opposed to the joint being evaluated.  Weight distribution in these horses 
was affected by the above issues and confounded force plate results.  In analyzing for 
differences, data was sorted to remove all horses with confounding lameness issues.  
Data from seven horses remained, and ANOVA revealed a P-value of 0.12 when 
comparing weight distribution between groups (Table 10).  These results could partially 
be explained by the small data set available for analysis, as well as a large variability 
between horses.  While accounting for standard errors in evaluating overlap of the data, 
it is also important to evaluate the mean total force plate values that were observed.  
While significant only at P = 0.12, the mean force plate value observed for horses in the 
treatment group was 5 times larger than the control.  
 
Table 10. Mean normalized weight (% of BW) placed on affected limb (+ SE) of 
osteoarthritic horses with and without n3 supplementation. 
Day Control (n = 4)  Treatment (n = 3) 
30 3.8 + 3.2 2.4 + 1.1 
   
60  -0.9 +1.6 4.7 + 2.7 
   
90  -2.1 + 0.08 2.85 + 1.8 
   
Totals 0.5 + 1.1a 2.5 + 0.9b 
a,b Values within rows lacking common subscripts differ (P = 0.12) 
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CHAPTER V 
DISCUSSION 
 
Fatty Acid Profiles 
 
 Treatment horses had significantly higher plasma DHA (C22:6n3) 
concentrations and lower LA (C18:2n6) concentrations. Arachidonic acid (C20:4n6) 
was also higher in treatment horses, and EPA (C20:5n3) was lower which did lead to an 
increase in the n6:n3 ratio in the plasma.  However, as noted earlier, DHA and LA are 
the main fatty acids which affect the n6:n3 ratio of both the diets and plasma between 
groups.  Therefore, the large difference in LA and DHA between groups greatly 
overwhelmed the negative effects of AA and EPA on the inflammatory state of 
treatment horses. 
 It is still unknown if one specific n3 fatty acid provides more anti-inflammatory 
benefits than others or if the ratio of total n6:n3 fatty acids is the key factor in reducing 
inflammation.  Previous studies evaluating the effect of n3s on arthritis focused more on 
increasing concentrations of EPA and DHA (Woodward et al., 2005), and decreasing 
concentrations of AA to alter the inflammatory potential of cells. However, this study 
provided evidence that decreasing the total n6:n3 ratio of the diet by increasing only 
DHA while decreasing LA was just as effective at reducing production of inflammatory 
markers. 
 
Inflammatory Markers 
 
Horses fed supplemental n3s experienced a decrease in plasma PGE2 and 
synovial fluid WBC concentration, as well as a trend towards decreased fibrinogen.  
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Fibrinogen is known to be a very broad marker of inflammation, and its presence in the 
blood indicates inflammation somewhere in the body.  The exact origin is not able to be 
determined, and while normal fibrinogen concentrations are between 100-400 mg/dl 
(Andrews et al., 1994), normal concentration for each horse is quite variable.  Small 
variations of fibrinogen due to reduced systemic inflammation would have been 
expected, but the differences seen here suggest the treatment horses may have 
experienced a decrease in total inflammation.  The lower concentrations (P< 0.05) 
observed when data from d 0 and 15 were removed also provided evidence that 
treatment horses experienced  reduced inflammation compared to control horses.  
Wilson (2003) found similar results in exercising horses.  Horses fed a diet containing 
soybean oil as a source of n3s were observed to have lower fibrinogen concentrations 
compared to horses consuming a diet containing supplemental corn oil. 
The negative change in plasma PGE2 of the horses fed supplemental n3s also 
indicated a decline in inflammation somewhere in the body.  Plasma PGE2 levels also 
demonstrated the likelihood that a decline was caused by a change in the fatty acid 
profile of the animal.  Because n6 fatty acids such as AA are known as the main 
precursor to inflammatory prostaglandins, a significant change in plasma PGE2 
concentrations was most likely due to a change in the fatty acid content of the cell 
membrane.  The decreased PGE2 concentration demonstrated a reduction in n6 fatty 
acids that may be explained by decreased concentrate intake and the addition of n3 
supplements to the diet of treatment horses.  
As previously noted, concentrations of plasma PGE2 and fibrinogen in both 
groups varied similarly as the study progressed.  After a separation of mean 
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concentrations, both plasma markers exhibited similar patterns throughout the trial, 
while treatment horses consistently had a lower mean concentration.  This could be an 
indicator of a well-controlled study in which any outside variables affected both groups 
equally.  Evidence of a controlled study increases the likelihood that the changes 
observed in inflammatory markers were caused by a treatment effect. 
Synovial WBC concentration represents the health of the joint and joint fluid, 
and is not greatly affected by other inflammatory processes occurring in the body.  
Compounds found in the serum or plasma reflect systemic characteristics and changes, 
and many joint-specific markers from synovial fluid may be eliminated by the time they 
reach the vascular system (Lohmander et al.,1992).  Although not the most sensitive 
marker of joint characteristics, synovial WBC concentration can be used to pinpoint 
changes specifically in joint health better than any compound found in the plasma.  In 
this study, a significant reduction in synovial WBC concentration suggested that at least 
a part of the decrease in inflammation indicated by plasma markers did indeed occur in 
the joint.  A lower WBC concentration in the synovial fluid of treatment horses 
provided evidence of a link between n3 fatty acids and the decreased joint inflammation 
and subsequent improvement of joint health.  As mentioned previously, further evidence 
of decreased joint disease was not obtained from force plate analysis or synovial 
cytokine analyses, though the force plate data does suggest a tendency toward increased 
weight placement on arthritic limbs. 
All markers of inflammation experienced some variation within the first 30 days 
of the study.  Specifically, the control horses had increased mean WBC and PGE2 
concentrations at d 15 and 30, and both groups experienced increased fibrinogen 
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concentrations at d 15.  Approximately 28 days of n3 supplementation is necessary to 
have any effect on the body (King et al., 2005), therefore changes before d 30 were most 
likely caused by other variables such as acclimation to diet and environment.  Since 
arthritic horses were obtained for this study from various sources across a large 
geographical area, a standard adjustment period was not possible.  Some horses from 
each group had more time to become accustomed to the study site than others.  In future 
studies, a longer pre-trial period is recommended to minimize potential for any 
confounding variables.  Also, many geriatric horses used in the study were not in good 
health or adequate body condition at the start of the trial.  The improved feed quality 
and consumption for these horses improved their overall body condition regardless of 
which diet they were receiving.  
Additional Applications 
This study used mostly geriatric horses with osteoarthritis due to age; however, 
other classes of horses, such as performance horses, are also subject to joint disease.  It 
has been shown that, while moderate exercise can stimulate bone and cartilage growth, 
intense exercise in animals leads to cartilage damage (Pap et al., 1998; Roos et al, 
1995).  Brama et al. (2000) found a significant increase in gross lesions in the cartilage 
as well as weakening of the collagen network in two-year old Thoroughbreds exercised 
in a typical race-training program.  It is likely that performance horses experiencing 
increased workloads will acquire joint damage faster than horses on low to moderate 
exercise protocols.  Therefore, the benefits of n3 PUFAs may also be applicable to the 
exercising horse.  It is common in the performance equine industry to feed additional fat 
as an energy source.  Research on polyunsaturated fatty acids has provided evidence 
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that n6s, such as that in corn oil, can have deleterious effects on system in the form of 
an increased ability to synthesize inflammatory mediators (Wilson, 2003).  The 
supplements provided to the treatment group in this study supplied those horses with 
additional n3s in the form of DPA (C22:5) and allowed for a decreased concentrate 
intake, and therefore reduced n6 consumption.  This resulted in a decrease in the plasma 
n6:n3 ratio which could be repeated to provide the same beneficial effects on joint 
health. At the same time, fat in the form of n3s can supply horses with the same positive 
effects as a traditional fat-supplemented diet such as decreased carbohydrate intake and 
reduced thermal load.  Therefore, n3s can be useful, not only to the osteoarthritic horse, 
but also to horses currently experiencing intense exercise.  
Osteoarthritis and other joint problems can certainly limit the usefulness of these 
animals after their competitive performance career has ended. Similar to geriatric 
horses, it is common for retired arthritic performance horses to be on daily medication 
such as phenylbutazone (bute) for pain management.  As mentioned earlier, continual 
high doses of NSAIDs can cause other problems such as stomach ulcers (MacAllister et 
al., 1993).  Because of this, an alternative treatment for inflammation caused by arthritis 
could be a major breakthrough for owners of retired performance horses.  
In addition to decreased inflammation in the joint, the decrease in plasma 
inflammatory markers could also be accounted for by a decrease in inflammation in 
other parts of the body.  Because plasma concentrations represent what is occurring 
systemically, it could be hypothesized that only part of the decrease in plasma 
fibrinogen and PGE2 was due to a decline in arthritic inflammation.  As mentioned 
earlier, most cell membranes in the body contain varying amounts of n6 and n3 PUFAs 
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depending on intake. Supplemental n3 consumption is expected to increase the amount 
of n3s in all cellular membranes. Therefore, additional n3s in the membranes of other 
cells in the body will decrease the inflammatory potential of those cells during insult or 
injury.   
Omega-3 PUFAs have been tested for many anti-inflammatory uses, other than 
arthritis.  Human researchers have investigated the possibility of using n3s for the 
treatment of cardiovascular disease, infertility, and to inhibit cancerous tumor growth.  
Mortality in men recovering from myocardial infarctions was decreased when patients 
consumed more fatty fish in their diet (Burr et al., 1989).  Omega-3s have the potential 
to be of benefit to asthma patients as well, due to their negative effect on LTB4 
production when compared to n6s (Okamoto et al., 2000).  Research has demonstrated 
the anti-inflammatory properties of n3s when consumed in adequate amounts in the diet.  
Further research is necessary to clarify the benefits of n3 supplementation on lameness 
due to arthritis as well as improving joint health and other physiological parameters in 
exercising horses. 
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CHAPTER VI 
 
SUMMARY 
 
 
Previous research has documented the positive effect of increased n3s in the diet 
on a variety of inflammatory responses.  An increase in n3 consumption, as well as a 
decrease in n6 consumption has been shown to decrease the production of inflammatory 
eicosanoids and cytokines, along with causing a reduction in pain in both humans and 
other animals.   
After 90 days of n3 supplementation, treatment horses experienced a decrease in 
inflammatory mediators both in the plasma and synovial fluid.  A significantly larger 
negative change in synovial fluid WBC concentration and plasma PGE2 concentration 
(P < 0.05) was seen in horses consuming supplemental n3s.  The decreased 
concentration of inflammatory markers in the synovial fluid indicated a reduction of 
joint inflammation and subsequent increase in joint health.  In addition, a trend (P = 
0.076) toward a larger negative change in plasma fibrinogen was also observed in 
treatment horses.  In analyzing weight distribution data from seven horses, a difference 
between groups was only significant at P = 0.12 suggesting the tendency of increased 
weight placement on arthritic limbs by treatment horses.  
Treatment horses also experienced decreased plasma n6:n3 ratio through both 
the reduction of LA (C18:2n6) and addition of DHA (C22:6n3) in their diets.  It is 
hypothesized that the decline in inflammation was due to a reduction of the total n6:n3 
ratio in the plasma of treatment horses.  These anti-inflammatory benefits can be 
valuable to the geriatric horse, along with exercising and retired performance horses.  
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APPENDICES 
 
APPENDIX 1. FATTY ACID PROFILE OF DIET COMPONENTS (% OF TOTAL FATTY ACIDS). 
Fatty acid Concentrate Coastal Hay Supp. A Supp. B 
C18:2n6 (LA) 42.11 18.20 5.50 7.41 
     
C18:3n6 (GLA) 0.001 0.005 0.002 0.004 
     
C18:3n3 (ALA) 3.50 15.62 1.16 2.24 
     
C20:3n6 (DGLA) 0.02 0.08 0.14 0.21 
     
C20:4n6 (AA) 0.03 0.20 0.32 0.72 
     
C20:5n3 (EPA) 0.11 0.72 0.10 0.07 
     
C22:5n3 (DPA) 0.02 0.08 0.03 0.03 
     
C22:6n3 (DHA) 0.17 1.41 3.73 17.93 
     
n6:n3 ratio 11.0:1 1.0:1 1.2:1 0.4:1 
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APPENDIX 2. FATTY ACID PROFILE OF DIET COMPONENTS (% OF DIET COMPONENT). 
Fatty acid Concentrate Coastal Hay Supp. A Supp. B 
C18:2n6 (LA) 2.430 0.231 0.575 1.075 
     
C18:3n6 (GLA) 0.003 0.006 0.016 0.052 
     
C18:3n3 (ALA) 0.202 0.190 0.121 0.325 
     
C20:3n6 (DGLA) 0.001 0.001 0.014 0.031 
     
C20:4n6 (AA) 0.002 0.003 0.034 0.104 
     
C20:5n3 (EPA) 0.007 0.009 0.010 0.019 
     
C22:5n3 (DPA) 0.001 0.002 0.003 0.004 
     
C22:6n3 (DHA) 0.009 0.017 0.389 2.600 
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APPENDIX 3. TOTAL FATTY ACID PROFILE OF DIET COMPONENTS (% OF DIET COMPONENT). 
Component C17:1 C18:0 C18:1n9t C18:1n11 C18:1n9c C18:1n7 C18:2n6t C18:2n6c C18:3n6 C18:3n3 C20:0 
            
Grain 0.00 0.15 0.05 0.000 1.69 0.06 0.004 2.39 0.003 0.206 0.001 
Hay 0.00 0.05 0.02 0.000 0.14 0.02 0.006 0.22 0.006 0.193 0.001 
Supp. A 0.03 0.55 0.07 0.038 1.12 0.39 0.076 0.49 0.016 0.121 0.020 
Supp. B 0.03 0.44 0.01 0.120 1.65 0.39 0.024 1.04 0.052 0.325 0.033 
Component C6:0 C8:0 C10:0 C11:0 C12:0 C14:0 C14:1 C15:0 C15:1 C16:0 C16:1 C17:0 
             
Grain 0.000 0.004 0.000 0.001 0.001 0.02 0.00 0.00 0.001 0.95 0.02 0.01 
Hay 0.000 0.002 0.000 0.001 0.017 0.05 0.00 0.01 0.001 0.34 0.05 0.01 
 Supp A 0.000 0.003 0.000 0.007 0.026 1.48 0.01 0.13 0.002 3.21 1.50 0.14 
Supp B 0.000 0.002 0.000 0.006 0.080 1.35 0.01 0.10 0.003 2.86 1.46 0.11 
Component C20:1 C20:2 C20:3n6 C20:4n6 C20:5n3 C21:0 C22:0 C22:5n3 C22:6n3 C24:0 C24:1 
            
Grain 0.046 0.002 0.001 0.001 0.006 0.002 0.001 0.001 0.009 0.008 0.024 
Hay 0.015 0.008 0.001 0.003 0.012 0.002 0.003 0.001 0.018 0.016 0.017 
Supp. A 0.119 0.091 0.014 0.033 0.009 0.012 0.005 0.003 0.381 0.267 0.010 
Supp. B 0.136 0.364 0.030 0.104 0.008 0.006 0.004 0.002 2.582 1.074 0.018 
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 APPENDIX 4. INDIVIDUAL FATTY ACID INTAKE (g) OF EVERY HORSE, EXCLUDING HAY.
Horse Treatment C8 C11:0 C12:0 C14:0 C14:1 C15:0 C15:1 C16:0 C16:1 C17:0 
1A Y 0.13 0.07 0.35 9.06 0.06 0.69 0.04 45.29 9.75 2.75 
2A Y 0.13 0.07 0.35 9.08 0.06 0.69 0.04 46.24 9.77 2.82 
3A Y 0.18 0.08 0.36 9.32 0.06 0.69 0.06 57.83 10.01 3.67 
4A Y 0.19 0.08 0.36 9.38 0.06 0.69 0.06 60.58 10.07 3.87 
5A Y 0.13 0.07 0.35 9.06 0.06 0.69 0.04 45.29 9.75 2.75 
6A Y 0.18 0.08 0.36 9.31 0.06 0.69 0.06 57.16 10.00 3.62 
7A Y 0.15 0.07 0.35 9.15 0.06 0.69 0.05 49.75 9.84 3.07 
8A Y 0.12 0.07 0.35 9.04 0.06 0.69 0.04 44.15 9.73 2.66 
1B N 0.20 0.05 0.05 1.00 0.00 0.00 0.05 47.60 1.00 3.51 
2B N 0.16 0.04 0.04 0.82 0.00 0.00 0.04 38.86 0.82 2.86 
3B N 0.21 0.05 0.05 1.06 0.00 0.00 0.05 50.26 1.06 3.70 
4B N 0.20 0.05 0.05 1.02 0.00 0.00 0.05 48.36 1.02 3.56 
5B N 0.18 0.04 0.04 0.89 0.00 0.00 0.04 42.18 0.89 3.11 
6B N 0.20 0.05 0.05 0.99 0.00 0.00 0.05 47.03 0.99 3.47 
7B N 0.16 0.04 0.04 0.80 0.00 0.00 0.04 38.19 0.80 2.81 
8B N 0.18 0.05 0.05 0.91 0.00 0.00 0.05 43.13 0.91 3.18 
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APPENDIX 4 CONTINUED. 
Horse Treatment C17:1 C18:0 C18:1n9 C18:1n11 C18:1n7 18:2n6 18:3n3 18:3n6 C20:0 C20:1 
1A Y 0.18 10.28 58.40 0.47 4.05 74.18 7.02 0.29 0.18 2.05 
2A Y 0.18 10.43 60.15 0.47 4.11 76.61 7.22 0.29 0.19 2.09 
3A Y 0.18 12.26 81.50 0.47 4.84 106.25 9.66 0.33 0.20 2.64 
4A Y 0.18 12.69 86.57 0.47 5.02 113.30 10.24 0.34 0.20 2.77 
5A Y 0.18 10.28 58.40 0.47 4.05 74.18 7.02 0.29 0.18 2.05 
6A Y 0.18 12.15 80.27 0.47 4.80 104.55 9.52 0.33 0.20 2.61 
7A Y 0.18 10.98 66.62 0.47 4.33 85.60 7.96 0.30 0.19 2.26 
8A Y 0.18 10.10 56.30 0.47 3.98 71.26 6.78 0.29 0.18 1.99 
1B N 0.00 7.52 87.68 0.00 3.01 121.74 10.02 0.15 0.05 2.25 
2B N 0.00 6.14 71.58 0.00 2.45 99.39 8.18 0.12 0.04 1.84 
3B N 0.00 7.94 92.58 0.00 3.17 128.55 10.58 0.16 0.05 2.38 
4B N 0.00 7.64 89.08 0.00 3.05 123.69 10.18 0.15 0.05 2.29 
5B N 0.00 6.66 77.70 0.00 2.66 107.89 8.88 0.13 0.04 2.00 
6B N 0.00 7.43 86.63 0.00 2.97 120.29 9.90 0.15 0.05 2.23 
7B N 0.00 6.03 70.35 0.00 2.41 97.69 8.04 0.12 0.04 1.81 
8B N 0.00 6.81 79.45 0.00 2.72 110.32 9.08 0.14 0.05 2.04 
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APPENDIX 4 CONTINUED. 
Horse Treatment C20:2 20:3n6 20:4n6 20:5n3 C21:0 C22:0 22:5n3 22:6n3 C24:0 C24:1 
1A Y 1.46 0.16 0.45 0.27 0.11 5.55 0.05 9.22 4.28 0.85 
2A Y 1.46 0.16 0.45 0.28 0.11 5.65 0.05 9.23 4.29 0.88 
3A Y 1.50 0.17 0.47 0.37 0.14 6.87 0.06 9.34 4.40 1.21 
4A Y 1.50 0.18 0.48 0.39 0.14 7.16 0.07 9.37 4.42 1.29 
5A Y 1.46 0.16 0.45 0.27 0.11 5.55 0.05 9.22 4.28 0.85 
6A Y 1.49 0.17 0.47 0.36 0.14 6.80 0.06 9.34 4.39 1.19 
7A Y 1.47 0.17 0.46 0.31 0.12 6.02 0.05 9.27 4.32 0.98 
8A Y 1.45 0.16 0.44 0.27 0.11 5.43 0.05 9.21 4.27 0.82 
1B N 0.15 0.05 0.10 0.35 0.10 5.01 0.05 0.45 0.45 1.35 
2B N 0.12 0.04 0.08 0.29 0.08 4.09 0.04 0.37 0.37 1.10 
3B N 0.16 0.05 0.11 0.37 0.11 5.29 0.05 0.48 0.48 1.43 
4B N 0.15 0.05 0.10 0.36 0.10 5.09 0.05 0.46 0.46 1.37 
5B N 0.13 0.04 0.09 0.31 0.09 4.44 0.04 0.40 0.40 1.20 
6B N 0.15 0.05 0.10 0.35 0.10 4.95 0.05 0.45 0.45 1.34 
7B N 0.12 0.04 0.08 0.28 0.08 4.02 0.04 0.36 0.36 1.09 
8B N 0.14 0.05 0.09 0.32 0.09 4.54 0.05 0.41 0.41 1.23 
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APPENDIX 5. AVERAGE INTAKE OF INDIVIDUAL FATTY ACIDS (g) BY GROUP, EXCLUDING HAY. 
           
Group C8 C11:0 C12:0 C14:0 C14:1 C15:0 C15:1 C16:0 C16:1 C17:0 
Treatment 0.15 0.07 0.35 9.18 0.06 0.69 0.05 50.78 9.87 3.15 
Control 0.19 0.05 0.05 0.94 0.00 0.00 0.05 44.45 0.94 3.28 
           
           
           
Group C17:1 C18:0 C18:1n9 C18:1n11 C18:1n7 18:2n6 18:3n3 18:3n6 C20:0 C20:1 
Treatment 0.18 11.14 68.52 0.47 4.40 88.24 8.18 0.31 0.19 2.31 
Control 0.00 7.02 81.88 0.00 2.81 113.69 9.36 0.14 0.05 2.11 
           
           
           
Group C20:2 20:3n6 20:4n6 20:5n3 C21:0 C22:0 22:5n3 22:6n3 C24:0 C24:1 
Treatment 1.47 0.17 0.46 0.32 0.12 6.13 0.06 9.28 4.33 1.01 
Control 0.14 0.05 0.09 0.33 0.09 4.68 0.05 0.42 0.42 1.26 
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APPENDIX 6. NORMALIZED PLASMA CONCENTRATIONS OF n6 AND n3 FATTY ACIDS. 
Fatty acid Control Treatment  Fatty acid Control Treatment 
C18:2 n6(LA)    C:20:4 n6 (AA)  
d 15 -24.9 -1.3  d 15 - 0.4 a 1.7 
d 30 -52.5 -1.9  d 30 -0.2 1.3 
d 45 -61.3 -2.7  d 45 0.7 1.5 
d 60 -71.4 -2.0  d 60 -0.4 1.5 
d 75 -97.1 -2.1  d 75 0.0 1.1 
d 90 -52.6 -0.1  d 90 -0.1 2.3 
Mean -51.4a -1.4  Mean -0.1 1.3b 
       
C18:3 n6 (GLA)    C20:5 n3 (EPA)   
d 15 -1.3 0.5  d 15 0.1 -0.6 
d 30 -1.9 -0.4  d 30 -0.3 -0.1 
d 45 -2.7 -2.7  d 45 -2.2a -0.4 
d 60 -2.0 -0.9  d 60 -0.5 0.2 
d 75 -2.1 -2.3  d 75 -0.4 -0.7 
d 90 -0.1 -2.2  d 90 -2.0 -0.6 
Mean -1.4 -1.2  Mean -0.7 -0.3 
       
C18:3 n3 (ALA)      C22:6 n3 (DHA)     
d 15 -16.8 -22.8  d 15 -0.7a 4.6 
d 30 -18.6 -23.5  d 30 -1.8a 5.3 
d 45 -19.6 -23.5  d 45 -1.1a 5.0 
d 60 -19.3 -24.7  d 60 -2.4a 2.9 
d 75 -23.8 -25.1  d 75 -2.8a 2.9 
d 90 -18.4 -23.8  d 90 -3.2a 2.8 
Mean -16.6 -20.5  Mean -1.7a 3.3b 
       
C20:3 (n6)      C22:5 n3 (DPA)   
d 15 0.1 -0.2  d 15 -0.4 -1.9 
d 30 -2.6 -0.5  d 30 -0.4 -0.8 
d 45 -1.0 0.7  d 45 0.2 -2.2 
d 60 -1.1 0.4  d 60 -0.4 -0.9 
d 75 -0.7 0.7  d 75 -0.1 -1.5 
d 90 -1.3 1.1  d 90 -0.3 -0.7 
Mean -0.6 0.3  Mean -0.2a -1.1b 
a,b Values between groups with differing superscripts differ P < 0.05.
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APPENDIX 7.  PLASMA FATTY ACID PROFILE OF EACH HORSE, REPORTED AS g/g OF PLASMA. 
Horse Trt Day C14:0 C14:1 C15:0 C15:1 C16:0 C16:1 C17:0 C17:1 
1A Y 0 42.5 11.0 16.3 2.9 835.1 71.1 19.3 10.8 
1A Y 15 18.5 8.8 16.0 4.2 240.8 28.9 12.0 8.8 
1A Y 30 18.5 8.8 16.0 4.2 240.8 28.9 12.0 8.8 
1A Y 45 17.4 8.5 15.1 4.5 234.7 28.4 13.5 6.7 
1A Y 60 17.2 15.2 12.8 4.4 193.4 22.6 10.1 5.9 
1A Y 75 19.9 4.0 13.4 3.6 225.7 26.9 11.4 5.0 
1A Y 90 15.1 6.9 14.7 3.1 219.1 28.2 10.3 5.4 
2A Y 0 46.4 12.9 10.9 4.3 924.5 81.6 22.6 12.5 
2A Y 15 10.0 4.0 13.1 2.9 183.1 18.3 9.9 4.7 
2A Y 30 14.8 6.6 14.2 4.4 161.2 19.0 10.7 6.5 
2A Y 45 11.0 11.0 12.2 4.9 161.9 21.1 13.8 6.8 
2A Y 60 16.3 7.8 10.0 5.7 147.6 21.2 11.8 4.9 
2A Y 75 11.9 4.4 9.8 1.9 145.2 17.0 11.4 0.7 
2A Y 90 12.0 43.8 47.1 1.7 138.3 15.0 8.2 3.0 
3A Y 0 14.2 5.0 9.8 3.6 241.1 26.5 11.7 6.9 
3A Y 15 15.1 7.9 16.1 5.9 204.9 19.8 15.6 6.9 
3A Y 30 14.5 4.7 12.9 3.6 219.0 19.3 10.2 6.2 
3A Y 45 13.3 6.3 11.3 3.6 202.7 17.4 8.6 7.5 
3A Y 60 10.9 4.2 12.2 2.9 186.7 15.7 9.3 7.1 
3A Y 75 11.9 8.1 8.3 3.0 192.4 18.2 13.2 8.0 
3A Y 90 11.4 3.9 10.0 0.9 191.8 18.1 16.6 4.2 
4A Y 0 18.9 7.4 9.9 4.4 237.1 27.6 9.8 8.8 
4A Y 15 15.0 5.3 7.2 2.0 193.3 16.1 9.1 3.7 
4A Y 30 14.3 4.0 6.4 2.1 168.6 14.2 11.1 5.9 
4A Y 45 13.7 6.1 9.2 0.4 186.1 13.7 13.8 4.6 
4A Y 60 11.3 7.3 6.7 0.0 182.2 19.0 15.7 5.9 
4A Y 75 13.6 7.0 5.5 2.7 170.1 17.1 10.2 5.2 
4A Y 90 15.9 7.0 6.4 0.4 187.0 20.8 11.2 3.7 
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APPENDIX 7 CONTINUED. 
Horse Trt Day C14:0 C14:1 C15:0 C15:1 C16:0 C16:1 C17:0 C17:1 
5A Y 0 15.1 6.3 6.2 4.6 167.3 23.7 9.1 6.3 
5A Y 15 15.4 5.2 10.7 1.9 147.2 21.7 13.4 7.3 
5A Y 30 15.0 16.7 13.9 5.3 136.4 19.3 10.1 7.5 
5A Y 45 11.7 6.0 7.7 2.5 127.1 18.4 11.3 6.6 
5A Y 60 9.5 6.2 7.7 1.9 110.7 15.2 2.2 5.5 
5A Y 75 11.8 7.7 6.7 2.2 112.3 15.4 9.5 1.4 
5A Y 90 14.4 3.4 11.9 3.2 132.9 20.1 9.6 5.0 
6A Y 0 11.4 2.6 12.1 4.2 182.7 21.8 9.9 5.3 
6A Y 15 17.2 6.9 13.9 2.0 176.8 16.5 9.0 6.4 
6A Y 30 16.8 7.0 11.6 3.2 192.3 18.6 8.4 5.8 
6A Y 45 15.3 5.0 14.7 1.2 178.0 18.6 13.3 4.1 
6A Y 60 13.7 5.9 9.5 4.2 166.5 16.2 14.2 3.7 
6A Y 75 13.0 4.4 7.2 3.1 160.8 14.0 8.5 5.1 
6A Y 90 14.8 6.1 3.8 4.0 173.5 17.6 9.5 3.9 
7A Y 0 11.0 4.7 11.0 4.8 203.2 24.7 36.9 10.3 
7A Y 15 14.5 7.9 16.6 2.8 209.5 26.6 17.0 6.3 
7A Y 30 15.1 7.2 12.4 4.5 171.9 20.9 13.4 5.4 
7A Y 45 12.2 4.9 11.1 3.0 158.0 20.4 12.7 6.1 
7A Y 60 14.8 6.7 13.4 1.9 152.5 19.2 12.9 5.4 
7A Y 75 10.1 10.0 8.6 2.9 139.4 16.2 9.4 4.0 
7A Y 90 10.4 6.6 8.2 2.9 162.0 18.2 12.1 5.9 
8A Y 0 7.8 4.4 11.1 5.1 190.0 12.8 12.5 6.3 
8A Y 15 14.2 7.5 12.6 1.9 167.4 18.2 10.8 5.4 
8A Y 30 15.9 7.9 11.6 1.1 195.7 26.4 13.9 5.7 
8A Y 45 16.2 6.8 17.0 2.8 197.6 24.1 14.9 4.9 
8A Y 60 18.6 5.6 10.7 3.5 196.1 23.8 13.2 6.5 
8A Y 75 15.0 4.6 17.5 3.2 206.8 20.6 10.5 5.8 
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APPENDIX 7 CONTINUED. 
Horse Trt Day C14:0 C14:1 C15:0 C15:1 C16:0 C16:1 C17:0 C17:1 
8A Y 90 12.5 7.7 3.3 5.5 179.4 21.5 10.9 4.7 
1B N 0 10.8 3.8 10.6 3.2 153.8 19.9 9.5 7.9 
1B N 15 12.7 5.6 12.9 1.6 180.6 15.2 12.3 6.5 
1B N 30 9.5 4.0 7.3 2.6 158.9 11.8 10.1 4.4 
1B N 45 12.4 5.6 11.3 4.6 183.5 12.0 11.8 8.5 
1B N 60 13.1 5.7 7.4 2.6 196.3 15.8 16.5 12.5 
1B N 75 7.0 5.3 3.0 2.8 151.7 12.0 9.2 7.6 
1B N 90 12.7 66.5 16.8 4.9 166.6 11.6 11.0 5.7 
2B N 0 13.0 6.6 10.1 2.2 180.9 18.9 13.2 6.7 
2B N 15 19.2 7.5 11.1 5.1 228.7 13.5 16.8 6.2 
2B N 30 12.2 8.6 8.4 2.3 186.5 13.3 11.9 8.6 
2B N 45 11.3 4.8 6.6 3.2 188.8 13.8 13.9 8.5 
2B N 60 12.3 7.2 10.5 2.0 212.1 15.3 11.9 10.5 
2B N 75 10.5 6.6 9.1 2.2 180.2 11.8 12.2 5.5 
2B N 90 16.8 8.5 7.4 2.9 198.3 15.8 12.6 5.1 
3B N 0 13.8 1.4 13.2 5.8 176.8 20.6 11.2 8.8 
3B N 15 16.5 5.3 13.3 2.8 191.0 15.8 11.3 5.6 
3B N 30 10.0 1.8 8.5 4.7 150.5 7.4 8.6 4.1 
3B N 45 18.9 6.6 12.9 3.7 176.8 9.8 10.6 3.3 
3B N 60 11.0 8.3 10.5 3.7 165.7 11.6 9.1 7.2 
3B N 75 9.3 5.3 7.2 1.5 147.6 11.2 10.9 7.4 
3B N 90 11.8 5.5 9.3 3.3 178.3 14.3 11.3 9.2 
5B N 0 19.6 6.4 11.6 3.7 219.2 17.0 14.5 7.8 
5B N 15 14.8 6.2 8.4 3.2 201.0 12.3 10.8 5.5 
5B N 30 11.0 5.8 12.4 4.0 203.0 14.5 12.0 7.6 
5B N 45 12.9 6.6 9.9 3.6 189.4 12.0 8.9 5.1 
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APPENDIX 7 CONTINUED. 
Horse Trt Day C14:0 C14:1 C15:0 C15:1 C16:0 C16:1 C17:0 C17:1 
5B N 60 11.3 6.4 10.4 40.3 222.3 16.0 8.4 6.9 
5B N 75 11.7 4.8 8.0 3.9 193.8 14.9 9.8 6.7 
5B N 90 9.5 9.0 5.7 0.7 206.6 11.9 10.4 5.1 
6B N 0 11.4 4.6 10.6 2.6 154.6 12.7 12.7 5.8 
6B N 15 10.2 6.8 10.0 1.2 173.4 11.6 13.2 6.6 
6B N 30 16.5 4.3 7.7 0.0 153.2 8.5 14.0 5.3 
6B N 45 14.1 5.5 7.7 4.5 156.4 9.5 14.4 2.9 
6B N 60 11.2 10.1 9.3 2.6 175.4 9.2 10.3 6.6 
6B N 75 8.7 5.9 5.4 2.5 150.5 8.6 12.7 2.8 
6B N 90 7.7 7.8 6.4 2.7 157.8 7.7 14.4 4.3 
7B N 0 51.9 15.7 8.7 2.7 971.5 72.1 26.8 14.0 
7B N 15 14.5 7.4 11.2 2.1 247.2 19.3 9.6 6.8 
7B N 30 18.5 6.1 11.9 4.0 270.6 24.4 14.2 6.2 
7B N 45 17.7 6.6 8.6 1.3 244.4 15.8 10.5 6.4 
7B N 60 10.2 5.4 9.7 2.3 203.9 14.9 9.3 5.2 
7B N 75 12.2 5.5 9.4 1.7 219.1 12.0 8.2 4.4 
7B N 90 16.1 6.0 1.7 0.5 226.7 15.2 9.1 0.2 
8B N 0 17.9 5.9 10.1 2.3 192.5 15.9 13.3 6.0 
8B N 15 9.2 7.4 7.1 4.4 183.0 7.8 8.4 4.9 
8B N 30 17.3 5.9 7.9 4.7 257.0 13.7 14.4 6.9 
8B N 45 11.7 6.2 9.1 2.6 206.1 12.1 13.6 3.8 
8B N 60 11.0 5.6 9.7 2.8 204.6 10.2 15.6 4.5 
8B N 75 13.9 5.1 8.1 2.9 219.3 10.7 12.4 6.4 
8B N 90 11.5 4.2 20.4 20.6 185.9 14.1 11.5 4.9 
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APPENDIX 7 CONTINUED. 
Horse Trt Day C18:0 C18:1n9t C18:1n11 C18:1n9c C18:1n7 C18:2n6t C18:2n6c C18:2n6 
1A Y 0 370.7 6.2 0 410.5 34.8 3.3 1358.2 1361.5 
1A Y 15 237.6 9.9 0 118.6 21.9 5.2 861.5 866.7 
1A Y 30 237.6 9.9 0 118.6 21.9 5.2 861.5 866.7 
1A Y 45 230.4 13.6 0 113.4 23.2 2.7 806.2 808.9 
1A Y 60 194.7 47.6 0 173.4 49.2 6 687.8 693.8 
1A Y 75 199.5 8.6 0 113.4 23.3 2.6 790 792.6 
1A Y 90 201.2 8.5 0 105.5 19.2 4.4 703.3 707.7 
2A Y 0 375.4 4.7 0 528 41.8 5.8 1385.1 1390.9 
2A Y 15 170.2 6 0 95.5 17.8 7.9 611.1 619 
2A Y 30 163 6.2 0 79.2 17.1 3.6 537.6 541.2 
2A Y 45 162.9 10.4 0 79.4 17.9 3.1 517.4 520.5 
2A Y 60 153.5 10.6 0 73 17.3 5.2 470.7 475.9 
2A Y 75 136.6 6.2 0 71 14.4 1.3 454.1 455.4 
2A Y 90 139.8 1.6 0 69.3 15.9 2.5 464.6 467.1 
3A Y 0 216.5 3.4 3.6 126.5 14.8 5.6 663 668.6 
3A Y 15 190.7 6.5 0 81.6 19.2 5 595.8 600.8 
3A Y 30 164.8 6.9 0 76.1 15 1.9 506.5 508.4 
3A Y 45 154.2 2.1 0 66.8 13.4 4.1 504.3 508.4 
3A Y 60 139.2 3.1 0 62.8 11.5 3.9 457.9 461.8 
3A Y 75 145.1 6.2 0 65.8 15.4 6.9 481.6 488.5 
3A Y 90 162.8 2 0 74.4 15.4 6.3 553.6 559.9 
4A Y 0 223.4 3.4 0 222 15.2 4 663.6 667.6 
4A Y 15 192.2 5 0 103.7 14.9 4 646.6 650.6 
4A Y 30 166.3 3.5 0 89 12.9 5.8 561.8 567.6 
4A Y 45 174.9 3.1 0 96.1 13.7 2.2 598.4 600.6 
4A Y 60 177.1 2.8 0 91.8 14 1.2 626.2 627.4 
4A Y 75 173.3 2.7 0 92.5 14.2 3.4 610.9 614.3 
4A Y 90 185.2 2.2 0 109.2 15.8 5.5 632 637.5 
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APPENDIX 7 CONTINUED. 
Horse Trt Day C18:0 C18:1n9t C18:1n11 C18:1n9c C18:1n7 C18:2n6t C18:2n6c C18:2n6 
5A Y 0 189.7 9.1 0 106.4 17.7 4.2 719.2 723.4 
5A Y 15 210 11.4 0 115.1 18 2.4 747.6 750 
5A Y 30 178.5 8.3 0 96.8 17.5 6.4 717.1 723.5 
5A Y 45 177.3 3.7 0 90 15.2 4 676.2 680.2 
5A Y 60 183.2 14.3 0 95.4 16.4 8.1 709.4 717.5 
5A Y 75 175.4 1.5 0 95 16.8 8.5 700.9 709.4 
5A Y 90 236 9.7 3.4 148.3 11.9 3.9 670.9 674.8 
6A Y 0 175.7 10 0 92.2 13.9 4.5 612.3 616.8 
6A Y 15 174.9 9.7 0 105.6 14 4.8 633.1 637.9 
6A Y 30 167.9 7.5 0 95.3 13.9 7.4 616.8 624.2 
6A Y 45 152.8 8.3 0 86 11.7 3.9 546.4 550.3 
6A Y 60 157.9 2.3 0 79.1 10.5 5.6 552.4 558 
6A Y 75 162 3.3 0 93.4 11.9 4.9 605.1 610 
6A Y 90 208.2 3.6 0 107.6 15.8 8.8 758.8 767.6 
7A Y 0 188.5 11.2 0 104.8 21.8 3.3 683.8 687.1 
7A Y 15 168.1 6.3 0 80.7 18.6 4.5 599.3 603.8 
7A Y 30 146.8 10.9 0 71.4 17.1 3.1 550.6 553.7 
7A Y 45 130.6 5.8 0 70.2 14.4 5.3 483.5 488.8 
7A Y 60 134.8 1.8 0 66.9 12.1 5.7 509.2 514.9 
7A Y 75 159.2 13.3 0 74.9 17.2 7.4 608.1 615.5 
7A Y 90 188.5 4.5 3.6 106.7 10.6 5.9 796.9 802.8 
8A Y 0 167.1 5.6 0 77 14.1 2.9 682.3 685.2 
8A Y 15 178.9 5.1 0 102.4 15.7 4.4 702.3 706.7 
8A Y 30 187.4 3.2 0 99.7 15.8 5.3 738.3 743.6 
8A Y 45 184 6.2 0 100.5 16.5 4.4 747.1 751.5 
8A Y 60 201.8 3.6 0 103.6 16.9 3.7 786.9 790.6 
8A Y 75 170.3 7.7 0 87.6 16 6.9 712 718.9 
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APPENDIX 7 CONTINUED. 
Horse Trt Day C18:0 C18:1n9t C18:1n11 C18:1n9c C18:1n7 C18:2n6t C18:2n6c C18:2n6 
8A Y 90 183.4 3.3 2.1 111 12 5.3 568.6 573.9 
1B N 0 223.9 3.9 0 125.4 13 5.4 788.5 793.9 
1B N 15 190.5 1.8 0 113.8 11.1 4.3 739.3 743.6 
1B N 30 200.1 8.4 0 133.7 14.7 9.4 770.8 780.2 
1B N 45 1.2 9.2 0 149.2 12.7 7.1 796.8 803.9 
1B N 60 184.7 0.7 0 103.9 8.9 5.5 672.5 678 
1B N 75 185.3 1.3 0 125.9 11.3 18.2 727.7 745.9 
1B N 90 214.7 6.5 4.6 124.8 13.2 5 837.6 842.6 
2B N 0 214.9 7.1 0 169.5 14.8 6.1 814 820.1 
2B N 15 192.4 8.2 0 150.8 11.1 4.7 722.1 726.8 
2B N 30 197.2 4.2 0 158.6 12 3.8 738.1 741.9 
2B N 45 217.5 4 0 183.2 12.2 6 783.9 789.9 
2B N 60 195.8 14.7 0 145.7 10.7 6.4 717.4 723.8 
2B N 75 203.2 5.6 0 154.3 12.9 1 775.1 776.1 
2B N 90 197.6 1.8 3.4 132.5 11.5 6.3 691.6 697.9 
3B N 0 204.6 8 0 138.9 13.8 4 840.2 844.2 
3B N 15 173.3 8.1 0 99.9 10.4 4 713.3 717.3 
3B N 30 173.9 8.2 0 114 10.8 4.3 730.6 734.9 
3B N 45 157.5 3.6 0 113.4 8.8 3.9 653.5 657.4 
3B N 60 151.9 4.8 0 98.1 9.6 0.6 615.9 616.5 
3B N 75 177.9 5.7 0 118.6 11.4 4.8 765.3 770.1 
3B N 90 190 4.6 0 96.1 12.4 2.1 671.8 673.9 
5B N 0 220 6.2 0 115.4 13.6 2.3 766.5 768.8 
5B N 15 173.7 6.5 0 117.3 9.8 5.8 572.2 578 
5B N 30 160.4 4.7 0 116.2 8.3 0.2 576.3 576.5 
5B N 45 174.6 6.5 0 135.4 10.7 4 577.9 581.9 
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APPENDIX 7 CONTINUED. 
Horse Trt Day C18:0 C18:1n9t C18:1n11 C18:1n9c C18:1n7 C18:2n6t C18:2n6c C18:2n6 
5B N 60 174.6 6.5 0 135.4 10.7 4 577.9 581.9 
5B N 75 159.2 6.1 0 110.3 10.9 5.2 562.4 567.6 
5B N 90 186 3.5 0 106.1 9.7 3.9 653.8 657.7 
6B N 0 213.3 10.6 0 155.2 12.8 5.1 670.6 675.7 
6B N 15 181.4 6.1 0 143.2 10.8 4.4 675.4 679.8 
6B N 30 215.9 4.1 0 158.3 13.3 5.3 689.4 694.7 
6B N 45 179 2.7 0 141.6 10.9 1 629.2 630.2 
6B N 60 201.5 1.6 0 169.5 12.6 1.6 684 685.6 
6B N 75 182.4 5.9 0 135.7 12.2 6.3 672.5 678.8 
6B N 90 185.8 3.6 0 149.4 13.2 7.9 705.2 713.1 
7B N 0 200.9 0.6 0 121.2 12 6.7 745.7 752.4 
7B N 15 176.2 4.2 0 125 10.1 3.5 721.9 725.4 
7B N 30 240.8 2.5 0 196.1 13.8 6 893.7 899.7 
7B N 45 228.1 6.3 0 147.4 11.9 6 880.8 886.8 
7B N 60 228.6 9.9 0 139.5 12.4 5.9 906.7 912.6 
7B N 75 269 6 0 167.4 18.1 18.8 897.4 916.2 
7B N 90 226.2 4.2 0 123.1 13.7 7 872.3 879.3 
8B N 0 385.8 11.4 0 534.1 41.7 3.4 1529 1532.4 
8B N 15 237.7 7.1 0 174.6 19 5.7 936.2 941.9 
8B N 30 258.5 12 0 185.6 18.8 5.4 1016.1 1021.5 
8B N 45 260.1 8.1 0 164.1 17.5 5.9 963 968.9 
8B N 60 211.6 9.3 0 134.9 14.5 1.2 816.5 817.7 
8B N 75 221.1 7.8 0 155.7 17.5 6.3 882.2 888.5 
8B N 90 190.8 3.3 0 142.7 16 1.2 837 838.2 
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APPENDIX 7 CONTINUED. 
Horse Trt Day C18:3n6 C18:3n3 C20:3n6 C20:4n6 C20:5n3 C22:5n3 C22:6n3 
1A Y 0 5.4 42.5 4.9 0.6 3.3 5.4 3.6 
1A Y 15 7.2 8.9 4.9 3.7 3.2 4 15.2 
1A Y 30 7.2 8.9 4.9 3.7 3.2 4 15.2 
1A Y 45 3.4 9.8 5.8 4.1 0.9 0.9 15.4 
1A Y 60 3.6 10.5 4.7 2.4 2.4 6.7 11.9 
1A Y 75 3.1 12.8 5.1 5.8 3.5 1.3 11.6 
1A Y 90 0.8 8.5 7.1 4.7 1.3 3.6 1.6 
2A Y 0 7.4 90.4 5.1 0.9 2.5 2.8 5 
2A Y 15 4.2 9.5 4.6 4 0 2 6.5 
2A Y 30 6.4 7.4 4.5 2.1 1.2 2.5 7.5 
2A Y 45 4.4 8.5 7 2 1.3 3.5 13.9 
2A Y 60 6.2 9 5.1 3.7 0.4 3.3 6.8 
2A Y 75 4.2 11.7 8.4 2.3 1.1 3.2 2 
2A Y 90 1.3 17.8 6.7 12.6 1.1 5.7 5.9 
3A Y 0 3.6 23.9 3.7 3.7 2.8 9.2 3.1 
3A Y 15 8.7 15 6 4 1.4 1.1 7.2 
3A Y 30 4.5 13.4 5.5 2.9 1.4 1.6 13.9 
3A Y 45 1.3 13.1 6.3 2.4 1.1 1.7 0.4 
3A Y 60 4.8 9.2 6.2 5.2 1.5 2.4 2.2 
3A Y 75 2.2 7.2 4.3 4.2 0 3.8 1.4 
3A Y 90 2.7 10.8 6.6 2.7 1 3.4 7.5 
4A Y 0 2.5 35.4 7.1 0 1.8 3.6 5.7 
4A Y 15 4.4 13.3 5.5 3.5 0 2.8 7.7 
4A Y 30 0.6 19.3 5.6 4.5 1.5 6.4 6.1 
4A Y 45 1.1 18.4 5.8 3.2 2.1 4.2 9.5 
4A Y 60 2.6 8.8 6.6 2 0 3.7 7.2 
4A Y 75 3.4 10.9 7.9 2.1 0 3.7 6.9 
4A Y 90 5.2 18.6 8.3 0.5 2 3.7 8.6 
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APPENDIX 7 CONTINUED. 
Horse Trt Day C18:3n6 C18:3n3 C20:3n6 C20:4n6 C20:5n3 C22:5n3 C22:6n3 
5A Y 0 7.6 26.3 4.3 0 0.4 0.9 4 
5A Y 15 6 13.6 5.3 2.2 2.3 2 8.7 
5A Y 30 4.8 12 4.9 2.8 0 1.7 9.2 
5A Y 45 1.5 12.6 5.5 3.3 1.3 2.8 17.9 
5A Y 60 4.6 8.7 5.5 4.2 1.4 1.9 9.1 
5A Y 75 2.9 9.7 6 1.1 2.1 2.5 0.9 
5A Y 90 2.7 10 6 1.8 0 3.6 10.6 
6A Y 0 2.7 24.5 5.9 4.5 0.8 5 6.4 
6A Y 15 4.2 11.7 7.3 3.2 0 4 9.9 
6A Y 30 5.8 17.4 7.1 2.5 1.4 3.7 7.7 
6A Y 45 3.1 18.9 9 5.5 1.2 0 5.5 
6A Y 60 6.5 17.3 6.6 2.8 1.3 3.4 6.8 
6A Y 75 2.4 11.2 6.3 1.8 1.4 3.8 8.1 
6A Y 90 4.8 13.8 4.7 2.4 2.3 0.7 6.6 
7A Y 0 6.1 21.9 9.2 4.1 1.7 3.5 8.6 
7A Y 15 6.4 25.3 5.9 3.8 0.9 0.6 9.3 
7A Y 30 2.4 12 5.1 4.1 0 1.8 10 
7A Y 45 1.5 13.3 5.2 3.9 0 1.9 9.6 
7A Y 60 5.2 19 5.1 2.4 7.6 1.7 8.2 
7A Y 75 3.5 15.1 5.3 0.8 0 2.9 21.9 
7A Y 90 3.5 11.6 9.1 5 0 3.6 13.6 
8A Y 0 6 27.8 6.8 1.5 0 3 4 
8A Y 15 4 13.1 6 4.3 1.1 1.5 12.7 
8A Y 30 6.5 14.3 5.8 2.8 3.5 5.1 13.1 
8A Y 45 3.2 10.2 7.8 3 2.5 1 8.1 
8A Y 60 0.4 13 10.3 4.2 0.4 3.4 11 
8A Y 75 1.5 13.2 9.4 6.2 0 0 10.7 
8A Y 90 2.4 11.3 7.3 4.2 0.6 3.7 8.3 
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APPENDIX 7 CONTINUED. 
Horse Trt Day C18:3n6 C18:3n3 C20:3n6 C20:4n6 C20:5n3 C22:5n3 C22:6n3 
1B N 0 6.6 25.8 9.4 0.5 3.3 1 4.9 
1B N 15 6.1 14.3 7.1 2.4 2.9 2.5 5 
1B N 30 3.3 10.4 4.6 2 5.9 3.8 6 
1B N 45 3.2 15.2 8 2.4 0.4 3.5 7.1 
1B N 60 1.7 10.9 6.5 1.3 1.2 2.9 3.8 
1B N 75 3.8 6.9 7.8 0 2.8 3.7 5.5 
1B N 90 2.6 22.5 6.2 4.5 1 2.5 1.6 
2B N 0 2.9 30.9 8.5 3.5 0.8 0.7 8.9 
2B N 15 3.1 28.7 7.1 1.2 4.2 1.7 5.8 
2B N 30 6.2 16.8 4.4 3.3 1.2 2.1 0.2 
2B N 45 2.2 17.9 7.4 4 1.5 1.1 1.3 
2B N 60 4.6 19.2 9.7 0.7 4.2 2 3.4 
2B N 75 3.9 16.9 9.9 0 0 2.1 0 
2B N 90 3.2 17.9 9 1.6 1.7 2.6 0.7 
3B N 0 5.6 19.3 4.1 0.9 4.4 1.2 4.6 
3B N 15 2.3 21 8 1.3 2.7 1.6 4.3 
3B N 30 3.7 12.5 9.1 1.4 0 2 4.8 
3B N 45 1.6 15.7 6 0.1 1.1 2.3 4.4 
3B N 60 2 16 5.1 2.2 2.9 3.4 3.4 
3B N 75 2.7 9.2 5.3 3.7 2.2 3.6 1.6 
3B N 90 3.3 19 15.7 1.1 0 2.9 3.2 
5B N 0 6.2 14.2 4.8 0.5 2.3 5.9 5.8 
5B N 15 4.3 17.1 6.7 0 3.9 5 6.1 
5B N 30 4.9 19 3.1 0 0 3.9 2.7 
5B N 45 0 18.2 5.1 3.3 3.1 3.6 4 
5B N 60 1.5 18.7 3.7 0.7 3.1 0.2 1 
5B N 75 1.8 12.9 4.3 0 1.6 3.7 3 
5B N 90 1.5 13.2 5.9 1.2 4.5 4 2.9 
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APPENDIX 7 CONTINUED. 
Horse Trt Day C18:3n6 C18:3n3 C20:3n6 C20:4n6 C20:5n3 C22:5n3 C22:6n3 
6B N 0 1.8 44.5 8.5 3.5 4.5 3.8 3.1 
6B N 15 5.7 24.8 8.1 3.5 2.9 3.4 2.3 
6B N 30 0.7 15.4 1.1 2.6 3.1 2.1 4.7 
6B N 45 5 16.3 6.2 2.6 0 5 4.8 
6B N 60 9.3 21.6 6.8 2.3 0 4.7 2.8 
6B N 75 3.1 10.1 7.3 3.1 1.7 3.8 2.5 
6B N 90 2.5 14 9.8 0 2.1 3.5 2.9 
7B N 0 2.4 28.8 5.5 1.2 0.6 4 3.7 
7B N 15 4.7 14.4 7.4 1 0.6 0.2 4.8 
7B N 30 3.9 29.4 4.9 1.4 0 3.6 1.1 
7B N 45 4.2 15.4 5 2.8 2.5 3.1 3.3 
7B N 60 5.5 18.9 6.2 1.2 1.3 0.6 2.8 
7B N 75 6.7 17 4 3.7 2.8 2.3 2 
7B N 90 16.7 21.7 6.4 2.5 3.2 2.1 2.3 
8B N 0 14 90.3 8.5 2 2.8 3.9 5.6 
8B N 15 4.5 16.2 5.6 0.1 3.8 3.4 3.6 
8B N 30 3.4 20 4.1 0 3.4 0 4.4 
8B N 45 4.2 17.6 4.7 1.7 5.1 3.4 3.8 
8B N 60 1.1 13.2 3.3 1.1 2.3 3.9 2.4 
8B N 75 3.1 13.9 6 1.3 2.1 0.7 2.3 
8B N 90 9 17 5.7 0.5 4.4 0.9 0.4 
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APPENDIX 8.  DAILY GROSS ENERGY (Mcal) OF EACH HORSE.  
 
 
 
 
APPENDIX 9. MEAN PLASMA PGE2 BY TREATMENT AND DAY. 
            Concentrations (pg/ml)            Normalized values 
Day Control Treatment Control Treatment 
0 2191 + 1381 2135 + 1378 0 0 
15 2436 +1248 1689 + 700 245 + 609 -446 + 771 
30 2712 + 1539 1721 + 812 521 + 227 -414 + 729 
45 2680 + 1387 1506+ 833 448 + 695 -628 + 566 
60 2764 + 1363 1635 + 928 573 + 703 -500 + 456 
75 2574 + 1130 1382 + 530 383 + 987 -753 + 1071 
90 3765 + 1592 1939 + 875 1573 + 1311 -196 +754 
Total 2732 + 494 1715 + 319 540 + 278 -420 + 247 
 
Horse 
Weight 
(lbs) T 
Grain 
intake/day (g) 
Grain 
(Mcal)) 
Supp A 
(Mcal) 
Supp B 
(Mcal) 
Hay 
(Mcal) Total(Mcal) 
1A 816 Y 2854.55 11.55 1.52 1.54 25.18 39.79 
2A 838 Y 2945.45 11.92 1.52 1.54 25.18 40.16 
3A 1108 Y 4172.73 16.88 1.52 1.54 25.18 45.12 
4A 1171 Y 4463.64 18.06 1.52 1.54 25.18 46.30 
5A 818 Y 2854.55 11.55 1.52 1.54 25.18 39.79 
6A 1092 Y 4100.00 16.59 1.52 1.54 25.18 44.83 
7A 920 Y 3318.18 13.43 1.52 1.54 25.18 41.67 
8A 1164 Y 2727.27 11.03 1.52 1.54 25.18 39.27 
1B 1102 N 5009.09 20.27 - - 25.18 45.45 
2B 1160 N 4090.91 16.55 - - 25.18 46.51 
3B 1163 N 5290.91 21.41 - - 25.18 46.59 
4B 1120 N 5090.91 20.60 - - 25.18 45.78 
5B 976 N 4436.36 17.95 - - 25.18 43.13 
6B 1088 N 4945.45 20.01 - - 25.18 45.19 
7B 884 N 4018.18 16.26 - - 25.18 41.44 
8B 998 N 4536.36 18.35 - - 25.18 43.53 
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APPENDIX 10.  MEAN PLASMA FIBRINOGEN BY TREATMENT AND DAY. 
       Concentrations (mg/dl)               Normalized 
Day Control Treatment Control Treatment 
0 398 + 15 466 + 30 0 0 
15 426 + 43 502 + 33 28 + 46 35 + 36 
30 420 + 17 437 + 39 22 + 25  -29 + 36 
45 375 + 20 396 + 30  -22 + 26  -70 + 27 
60 365 + 28 397 + 17  -48 + 19  -87 + 34 
75 371 + 17 406 + 26  -42 + 15  -78 + 39 
90 387 + 19 418 + 32  -26 + 24  -66 + 44 
Total 394 + 10 433 + 12 -10 + 10 -40 + 13 
 
 
 
 
APPENDIX 11.  MEAN SYNOVIAL FLUID WBC BY TREATMENT AND DAY. 
       Concentrations (cells/ml)              Normalized 
Day Control Treatment Control Treatment 
0 336 + 80 382 + 96 0 0 
30 888 + 698 172 + 75 582 + 661 -199 + 149 
60 200 + 67 66 + 11 -136 + 61 -316 + 100 
90 343 + 136 72 + 9 5 + 84 -388 + 124 
Total 420 + 155 181 + 38 90 + 144 -214 + 55 
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APPENDIX 12. PLASMA PGE2 AND FIBRINOGEN FOR ALL HORSES. 
Horse Day Trt (Y/N) 
 PGE2 
(pg/ml) 
Fibrinogen 
 (mg/dl) 
1A 0 Y 487 569 
1A 15 Y 1074 579 
1A 30 Y 235 536 
1A 45 Y 111 477 
1A 60 Y 403 393 
1A 75 Y 476 402 
1A 90 Y 600 439 
2A 0 Y 1914 374 
2A 15 Y 2071 523 
2A 30 Y 2267 427 
2A 45 Y 1407 384 
2A 60 Y 1211 433 
2A 75 Y 1497 446 
2A 90 Y 1885 480 
3A 0 Y 10301 589 
3A 15 Y * 485 
3A 30 Y 5885 451 
3A 45 Y 6372 439 
3A 60 Y 7150 410 
3A 75 Y 3069 445 
3A 90 Y 6309 416 
4A 0 Y 952 492 
4A 15 Y 2350 383 
4A 30 Y 2881 273 
4A 45 Y 1388 299 
4A 60 Y 1119 331 
4A 75 Y 3194 275 
4A 90 Y 4760 301 
5A 0 Y 201 481 
5A 15 Y 127 635 
5A 30 Y * 500 
5A 45 Y 265 482 
5A 60 Y 399 439 
5A 75 Y * 470 
5A 90 Y 314 533 
6A 0 Y 9880 428 
6A 15 Y * 500 
6A 30 Y 20989 358 
6A 45 Y 13759 326 
6A 60 Y * 338 
6A 75 Y 12194 348 
6A 90 Y 11717 308 
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APPENDIX 12 CONTINUED.  
Horse Day Trt (Y/N) 
 PGE2 
(pg/ml) 
Fibrinogen 
 (mg/dl) 
7A 0 Y 873 461 
7A 15 Y 626 555 
7A 30 Y 504 456 
7A 45 Y 507 485 
7A 60 Y 802 440 
7A 75 Y 735 456 
7A 90 Y * 450 
8A 0 Y * 341 
8A 15 Y 171 361 
8A 30 Y 215 358 
8A 45 Y 495 282 
8A 60 Y 361 334 
8A 75 Y 286 312 
8A 90 Y * 329 
1B 0 N 10258 380 
1B 15 N 8348 352 
1B 30 N 11308 312 
1B 45 N 8977 409 
1B 60 N 8909 360 
1B 75 N * 367 
1B 90 N 9183 397 
2B 0 N * 471 
2B 15 N 392 349 
2B 30 N 390 334 
2B 45 N 411 300 
2B 60 N 593 412 
2B 75 N 358 372 
2B 90 N 319 333 
3B 0 N 99 439 
3B 15 N 253 507 
3B 30 N 53 498 
3B 45 N 68 456 
3B 60 N 311 466 
3B 75 N 171 448 
3B 90 N 31 454 
4B 0 N * 372 
4B 15 N * 690 
4B 30 N * 507 
4B 45 N 3461 393 
4B 60 N * 731 
4B 75 N * * 
4B 90 N * * 
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APPENDIX 12 CONTINUED.  
Horse Day Trt (Y/N) 
 PGE2 
(pg/ml) 
Fibrinogen 
 (mg/dl) 
5B 0 N 528 387 
5B 15 N 754 327 
5B 30 N 830 329 
5B 45 N 867 365 
5B 60 N 328 298 
5B 75 N 5052 357 
5B 90 N 9039 371 
6B 0 N 2457 380 
6B 15 N 5935 360 
6B 30 N 4418 380 
6B 45 N 6938 285 
6B 60 N 7032 277 
6B 75 N 9060 320 
6B 90 N 5202 340 
7B 0 N 1451 425 
7B 15 N 1115 450 
7B 30 N 1660 377 
7B 45 N 836 414 
7B 60 N 1253 378 
7B 75 N 742 366 
7B 90 N * 421 
8B 0 N * 331 
8B 15 N 259 376 
8B 30 N 328 412 
8B 45 N 328 381 
8B 60 N 521 401 
8B 75 N 382 358 
8B 90 N 128 344 
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APPENDIX 13.  SYNOVIAL FLUID WBC FOR ALL HORSES. 
Horse Joint Day Trt (Y/N) 
Synovial Fluid  
WBC (cells/ml) 
1A Upper L Knee 0 Y 875 
1A Upper L Knee 30 Y 88 
1A Upper L Knee 60 Y 47 
1A Upper L Knee 90 Y 80 
1A Lower L Knee 0 Y 917 
1A Lower L Knee 30 Y 70 
1A Lower L Knee 60 Y 21 
1A Lower L Knee 90 Y 40 
2A Upper R Knee 0 Y 291 
2A Upper R Knee 30 Y 189 
2A Upper R Knee 60 Y 142 
2A Upper R Knee 90 Y 107 
2A Lower R Knee 0 Y 229 
2A Lower R Knee 30 Y 299 
2A Lower R Knee 60 Y 266 
2A Lower R Knee 90 Y 224 
3A Upper L Knee 0 Y 92 
3A Upper L Knee 30 Y 820 
3A Upper L Knee 60 Y 41 
3A Upper L Knee 90 Y 89 
3A Lower L Knee 0 Y 732 
3A Lower L Knee 30 Y 76 
3A Lower L Knee 60 Y 43 
3A Lower L Knee 90 Y 47 
4A Upper R Knee 0 Y 129 
4A Upper R Knee 30 Y 249 
4A Upper R Knee 60 Y 59 
4A Upper R Knee 90 Y 56 
4A Lower R Knee 0 Y 78 
4A Lower R Knee 30 Y 29 
4A Lower R Knee 60 Y 51 
4A Lower R Knee 90 Y 137 
5A Left Hind Fetlock 0 Y 488 
5A Left Hind Fetlock 30 Y 2250 
5A Left Hind Fetlock 60 Y 106 
5A Left Hind Fetlock 90 Y 105 
6A Upper R Knee 0 Y 193 
6A Upper R Knee 30 Y 89 
6A Upper R Knee 60 Y 122 
6A Upper R Knee 90 Y 74 
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APPENDIX 13 CONTINUED. 
Horse Joint Day Trt (Y/N) 
Synovial Fluid  
WBC (cells/ml) 
6A Lower L Knee 0 Y 106 
6A Lower L Knee 30 Y 48 
6A Lower L Knee 60 Y 38 
6A Lower L Knee 90 Y 41 
7A Left Hind Fetlock 0 Y 311 
7A Left Hind Fetlock 30 Y 68 
7A Left Hind Fetlock 60 Y 64 
7A Left Hind Fetlock 90 Y 94000 
8A Upper L Hock 0 Y 57 
8A Upper L Hock 30 Y 83 
8A Upper L Hock 60 Y 37 
8A Upper L Hock 90 Y 43 
8A Upper R Hock 0 Y 41 
8A Upper R Hock 30 Y 27 
8A Upper R Hock 60 Y * 
8A Upper R Hock 90 Y 49 
1B Upper R Knee 0 N 602 
1B Upper R Knee 30 N 2500 
1B Upper R Knee 60 N 316 
1B Upper R Knee 90 N 1160 
1B Lower R Knee 0 N 814 
1B Lower R Knee 30 N 542 
1B Lower R Knee 60 N 593 
1B Lower R Knee 90 N 678 
2B Upper L Knee 0 N 162 
2B Upper L Knee 30 N 500 
2B Upper L Knee 60 N 93 
2B Upper L Knee 90 N 93 
2B Lower L Knee 0 N 567 
2B Lower L Knee 30 N 5750 
2B Lower L Knee 60 N 107 
2B Lower L Knee 90 N 740 
3B Upper R Knee 0 N 111 
3B Upper R Knee 30 N 41 
3B Upper R Knee 60 N 31 
3B Upper R Knee 90 N 98 
3B Lower R Knee 0 N 102 
3B Lower R Knee 30 N 19 
3B Lower R Knee 60 N 32 
3B Lower R Knee 90 N 43 
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APPENDIX 13 CONTINUED. 
Horse Joint Day Trt (Y/N) 
Synovial Fluid  
WBC (cells/ml) 
4B Upper L Knee 0 N 184 
4B Upper L Knee 30 N 116 
4B Upper L Knee 60 N * 
4B Upper L Knee 90 N * 
4B Lower L Knee 0 N 105 
4B Lower L Knee 30 N * 
4B Lower L Knee 60 N * 
4B Lower L Knee 90 N * 
5B Left Hind Fetlock 0 N 305 
5B Left Hind Fetlock 30 N 85 
5B Left Hind Fetlock 60 N 146 
5B Left Hind Fetlock 90 N 93 
6B Left Front Fetlock 0 N 316 
6B Left Front Fetlock 30 N * 
6B Left Front Fetlock 60 N 550 
6B Left Front Fetlock 90 N * 
6B Right Front Fetlock 0 N 355 
6B Right Front Fetlock 30 N 46 
6B Right Front Fetlock 60 N 63 
6B Right Front Fetlock 90 N 48 
7B Upper R Knee 0 N 132 
7B Upper R Knee 30 N 121 
7B Upper R Knee 60 N 71 
7B Upper R Knee 90 N 142 
7B Lower R Knee 0 N 875 
7B Lower R Knee 30 N 122 
7B Lower R Knee 60 N 89 
7B Lower R Knee 90 N 109 
8B Right Stifle 0 N 174 
8B Right Stifle 30 N 341 
8B Right Stifle 60 N 481 
8B Right Stifle 90 N 161 
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APPENDIX 14. ANOVA FOR MEAN FIBRINOGEN CONCENTRATION (mg/dl). 
Source Partial SS df MS F Prob > F
Model 139193.32 13 10707.18 1.76 0.062 
Treatment 40864.72 1 40864.72 6.72 0.011 
Day 85903.32 6 14317.22 2.36 0.037 
Treatment by day 12626.16 6 2104.36 0.35 0.91 
Residual 540918.41 89 6.077.73   
Total 680111.72 102 6667.76     
 
 
APPENDIX 15. ANOVA FOR NORMALIZED MEAN FIBRINOGEN  
CONCENTRATIONS. 
Source Partial SS df MS F Prob > F
Model 161290.46 13 12406.95 1.79 0.057 
Treatment 22398.53 1 22398.53 3.22 0.076 
Day 122623.93 6 20437.32 2.94 0.011 
Treatment by day 13056.63 6 2176.1 0.31 0.928 
Residual 618575.51 89 6950.28   
Total 779865.98 102 6950.28     
 
 
APPENDIX 16. ANOVA FOR MEAN WBC CONCENTRATIONS (cells/ml). 
Source Partial SS df MS F Prob > F
Model 4144465.06 7 592066.43 1.31 0.25 
Treatment 1367337.35 1 1367337.35 3.02 0.08 
Day 1739802.73 3 579934.24 1.28 0.28 
Treatment by day 1495548.92 3 498516.3 1.1 0.35 
Residual 31211361.3 69 452338.56   
Total 35355826.3 76 465208.24     
 
 
APPENDIX 17.  ANOVA FOR NORMALIZED MEAN WBC CONCENTRATIONS. 
Source Partial SS df MS F Prob > F
Model 5246782.94 7 749540.42 1.76 0.1 
Treatment 2179617.2 1 2179617.2 5.13 0.02 
Day 2070631.73 3 690210.57 1.62 0.19 
Treatment by day 1610193.58 3 536731.19 1.26 0.29 
Residual 29311984.5 69 424811.37   
Total 34558767.5 76 454720.62     
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APPENDIX 18. ANOVA FOR MEAN PGE2 CONCENTRATIONS (pg/ml). 
Source Partial SS df MS F Prob > F
Model 38381057.7 13 2952389.06 0.31 0.98 
Treatment 25331233.4 1 25331233.4 2.65 0.1 
Day 7030586.97 6 1171764.5 0.12 0.99 
Treatment by day 6019237.4 6 1003206.23 0.11 0.99 
Residual 802102692 84 9548841.57   
Total 840483750 97 8664780.93     
 
 
APPENDIX 19. ANOVA FOR NORMALIZED MEAN PGE2 CONCENTRATIONS. 
Source Partial SS df MS F Prob > F
Model 35665711.3 13 2743516.25 0.73 0.72 
Treatment 22615886.9 1 22615886.9 6.05 0.01 
Day 7030586.97 6 1171764.5 0.31 0.92 
Treatment by day 6019237.4 6 1003206.23 0.27 0.95 
Residual 314001263 84 3738110.28   
Total 349666974 97 3604814.17     
 
 
APPENDIX 20. ANOVA FOR ENERGY INTAKE BY GROUP. 
Source Partial SS df MS F Prob > F
Model 15.82 1 15.82 2.67 0.12 
Treatment 15.82 1 15.82 2.67 0.12 
Residual 82.65 14 5.91   
Total 98.65 15 6.57     
 
 
APPENDIX 21. ANOVA FOR MEAN LINOLEIC ACID (C18:2) INTAKE. 
Source Partial SS df MS F Prob > F
Model 2511.30 1 2511.30 11.01 0.0056 
Treatment 2511.30 1 2511.30 11.01 0.0056 
Residual 2965.95 13 22.15   
Total 5477.25 148 391.23     
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APPENDIX 22. ANOVA FOR MEAN GAMMA LINOLEIC ACID (C18:3n6) INTAKE. 
Source Partial SS df MS F Prob > F
Model 0.105 1 0.105 275 0.0000 
Treatment 0.105 1 0.105 275 0.0000 
Residual 0.005 13 0.0004   
Total 0.11 14 0.008     
 
APPENDIX 23. ANOVA FOR MEAN ALPHA-LINOLENIC ACID (C18:3n3) INTAKE. 
Source Partial SS df MS F Prob > F
Model 5.55 1 5.55 3.59 0.0000 
Treatment 5.55 1 5.55 3.59 0.0000 
Residual 20.09 13 1.55   
Total 25.65 14 1.83     
 
APPENDIX 24. ANOVA FOR MEAN C20:3n6 INTAKE. 
Source Partial SS df MS F Prob > F
Model 0.05 1 0.054 1261 0.0000 
Treatment 0.05 1 0.054 1261 0.0000 
Residual 0.0006 13 0.00004   
Total 0.055 14 0.004     
 
APPENDIX 25. ANOVA FOR MEAN ARACHIDONIC ACID (C20:4n6) INTAKE. 
Source Partial SS df MS F Prob > F
Model 0.50 1 0.50 3131 0.0000 
Treatment 0.50 1 0.50 3131 0.0000 
Residual 0.002 13 0.0002   
Total .050 14 0.36     
 
APPENDIX 26. ANOVA FOR MEAN EICOSAPENTAENOIC ACID (C20:5n3) INTAKE. 
Source Partial SS df MS F Prob > F
Model 0.0008 1 0.0008 0.42 0.53 
Treatment 0.0008 1 0.0008 0.42 0.53 
Residual 0.025 13 0.002   
Total 0.026 14 0.002     
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APPENDIX 27. ANOVA FOR MEAN DOCOSAPENTAENOIC ACID (C22:5n3) INTAKE. 
Source Partial SS df MS F Prob > F
Model 292.5 1 292.5 88064 0.0000 
Treatment 292.5 1 292.5 88064 0.0000 
Residual 0.04 13 0.003   
Total 292.5 14 20.89     
 
APPENDIX 28. ANOVA FOR MEAN DOCOSAHEXAENOIC ACID (C22:6n3) INTAKE. 
Source Partial SS df MS F Prob > F
Model 0.0003 1 0.0003 7.32 0.02 
Treatment 0.0003 1 0.0003 7.32 0.02 
Residual 0.0006 13 0.00004   
Total 0.0009 14 0.00006     
 
APPENDIX 29. ANOVA FOR MEAN n3 FATTY ACID INTAKE. 
Source Partial SS df MS F Prob > F
Model 217.2 1 217.2 119.5 0.0000 
Treatment 217.2 1 217.2 119.5 0.0000 
Residual 23.6 13 1.82   
Total 240.9 14 17.21     
 
APPENDIX 30. ANOVA FOR MEAN n6 FATTY ACID INTAKE. 
Source Partial SS df MS F Prob > F
Model 2386 1 2386 10.41 0.0066 
Treatment 2386 1 2386 10.41 0.0066 
Residual 2980 13 229.3   
Total 5367 14 383.4     
 
APPENDIX 31. ANOVA FOR MEAN LINOLEIC ACID (C18:2n6) CONCENTRATIONS. 
Source Partial SS df MS F Prob > F
Model 797847 13 61372 2.45 0.007 
Treatment 258212 1 258212 10.3 0.0018 
Day 375453 6 62575 2.5 0.03 
Treatment by day 133739 6 22289 0.89 0.51 
Residual 2281332 91 25069   
Total 3079179 104 29069    
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APPENDIX 32. ANOVA FOR NORMALIZED MEAN LINOLEIC ACID (C18:2n6) 
CONCENTRATIONS. 
Source Partial SS df MS F Prob > F
Model 4949021 13 380693 69.6 0.0000 
Treatment 27895 1 27895 5.1 0.03 
Day 4875873 6 812645 148.5 0.0000 
Treatment by day 5313 6 885 0.2 1.0 
Residual 498132 91 5473   
Total 5447154 104 52376     
 
APPENDIX 33. ANOVA FOR MEAN GAMMA-LINOLENIC ACID (C18:3n6) CONCENTRATIONS. 
Source Partial SS df MS F Prob > F
Model 122 13 9.39 1.57 0.11 
Treatment 1.04 1 1.04 0.17 0.70 
Day 79.9 6 13.3 2.2 0.05 
Treatment by day 39.1 6 6.52 1.09 0.37 
Residual 544 91 6.0   
Total 666 104 6.4    
 
APPENDIX 34. ANOVA FOR NORMALIZED MEAN GAMMA-LINOLENIC ACID (C18:3n6) 
CONCENTRATIONS. 
Source Partial SS df MS F Prob > F
Model 3442795 13 264830 218 0.0000 
Treatment 1096 1 1096 0.9 0.34 
Day 3400710 6 566785 467.9 0.0000 
Treatment by day 6252 6 1042 0.9 0.53 
Residual 110235 91 1211   
Total 3553030 104 34163     
 
APPENDIX 35. ANOVA FOR MEAN ALPHA-LINOLENIC ACID (C18:3n3) CONCENTRATIONS. 
Source Partial SS df MS F Prob > F
Model 6724 13 517 .3 0.0000 
Treatment 319 1 319 3.3 0.07 
Day 6186 6 1031 105 0.0000 
Treatment by day 119 6 19 0.2 0.97 
Residual 8915 91 97   
Total 15639 104 150     
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APPENDIX 36. ANOVA FOR NORMALIZED MEAN ALPHA-LINOLENIC ACID (C18:3n3) 
CONCENTRATIONS. 
Source Partial SS df MS F Prob > F
Model 6787 13 522 1.0 0.5 
Treatment 382 1 382 0.7 0.4 
Day 6186 6 1031 1.9 0.09 
Treatment by day 119 6 19.9 0.04 1.0 
Residual 48914 91 537   
Total 55701 104 535     
 
APPENDIX 37. ANOVA FOR MEAN C20:3n6 CONCENTRATIONS. 
Source Partial SS df MS F Prob > F
Model 79.5 13 6.1 1.8 0.05 
Treatment 2.15 1 2.2 0.6 0.43 
Day 57.4 6 9.6 2.8 0.02 
Treatment by day 23.2 6 3.9 1.1 0.35 
Residual 310 91 3.4   
Total 389 104 3.7     
 
APPENDIX 38. ANOVA FOR NORMALIZED MEAN C20:3n6 CONCENTRATIONS. 
Source Partial SS df MS F Prob > F
Model 97.9 13 7.5 1.3 0.2 
Treatment 20.3 1 20.3 3.6 0.06 
Day 57.4 6 9.6 1.7 0.13 
Treatment by day 23.2 6 3.9 0.7 0.66 
Residual 509 91 5.6   
Total 606 104 5.8     
 
 
APPENDIX 39. ANOVA FOR MEAN ARACHIDONIC ACID (C20:4n6) CONCENTRATIONS. 
Source Partial SS df MS F Prob > F
Model 94.2 13 7.2 2.64 0.004 
Treatment 64.9 1 64.9 23.7 0.0000 
Day 13.1 6 2.2 0.8 0.6 
Treatment by day 14.9 6 2.5 0.9 0.50 
Residual 249.9 91 2.7   
Total 344 104 3.3     
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APPENDIX 40. ANOVA FOR NORMALIZED MEAN ARACHIDONIC ACID (C20:4n6) 
CONCENTRATIONS. 
Source Partial SS df MS F 
Prob > 
F 
Model 79.9 13 6.1 1.4 0.2 
Treatment 50.7 1 507 11.3 0.001 
Day 13.1 6 2.2 0.5 0.82 
Treatment by day 14.9 6 2.5 0.6 0.77 
Residual 408 91 4.5   
Total 488 104 4.7     
 
APPENDIX 41. ANOVA FOR MEAN EICOSAPENTAENOIC ACID (C20:5n3) CONCENTRATIONS. 
Source Partial SS df MS F 
Prob > 
F 
Model 35.4 13 2.7 1.2 0.3 
Treatment 22.5 1 22.5 10.2 0.002 
Day 6.0 6 1.0 0.5 0.8 
Treatment by day 7.1 6 1.2 0.5 0.8 
Residual 200 91 2.2   
Total 236 104 2.3     
 
APPENDIX 42. ANOVA FOR NORMALIZD MEAN EICOSAPENTAENOIC ACID (C20:5n3) 
CONCENTRATIONS. 
Source Partial SS df MS F 
Prob > 
F 
Model 46.9 13 3.6 1.5 0.13 
Treatment 5.0 1 5.0 2.1 0.15 
Day 26.1 6 4.4 1.8 0.10 
Treatment by day 17.9 6 3.0 1.3 0.300 
Residual 216 91 2.4   
Total 263 104 2.5     
 
APPENDIX 43. ANOVA FOR MEAN DOCOSAHEXAENOIC ACID (C22:6n3) CONCENTRATIONS. 
Source Partial SS df MS F 
Prob > 
F 
Model 843 13 94.9 6.0 0.0000
Treatment 325 1 625 57.8 0.0000
Day 91 6 15.2 1.4 0.22 
Treatment by day 120 6 20.1 1.9 0.09 
Residual 984 91 10.8   
Total 1828 104 17.6     
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APPENDIX 44. ANOVA FOR NORMALIZED MEAN DOCOSAHEXAENOIC ACID (C22:6n3) 
CONCENTRATIONS. 
Source Partial SS df MS F Prob > F 
Model 890 13 68 5.4 0.0000 
Treatment 671 1 671 52.6 0.0000 
Day 91.4 6 15.2 1.2 0.32 
Treatment by day 120 6 20 1.6 0.20 
Residual 1162 91 12.8   
Total 2053 104 19.7     
 
APPENDIX 45. ANOVA FOR MEAN DOCOSAPENTAENOIC ACID (C22:5n3) 
CONCENTRATIONS. 
Source Partial SS df MS F Prob > F 
Model 33.1 13 2.5 1.0 0.4 
Treatment 2.4 1 2.4 1.0 0.3 
Day 12.5 6 2.1 0.9 0.5 
Treatment by day 16.5 6 2.7 1.1 0.4 
Residual 221 91 2.4   
Total 254 104 2.5     
 
APPENDIX 46. ANOVA FOR NORMALIZED MEAN DOCOSAPENTAENOIC ACID (C22:5n3) 
CONCENTRATIONS. 
Source Partial SS df MS F Prob > F 
Model 54 13 4.2 0.7 0.75 
Treatment 23 1 23.3 4.0 0.048 
Day 12.5 6 2.1 0.4 0.90 
Treatment by day 16 6 2.7 0.5 0.83 
Residual 532 91 5.9   
Total 586 104 5.6     
 
APPENDIX 47. ANOVA FOR MEAN n6 CONCENTRATIONS. 
Source Partial SS df MS F Prob > F 
Model 793975 13 61075 2.4 0.008 
Treatment 252578 1 252578 10.0 0.002 
Day 381190 6 63531 2.5 0.03 
Treatment by day 130022 6 21670 0.9 0.53 
Residual 2304276 91 25321   
Total 3098251 104 29790     
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APPENDIX 48. ANOVA FOR NORMALIZED MEAN n6 CONCENTRATIONS. 
Source Partial SS df MS F Prob > F
Model 1282405 13 98646 1.4 0.20 
Treatment 741009 1 741009 10.2 0.002 
Day 381190 6 63531 0.9 0.52 
Treatment by day 130022 6 21670 0.3 0.94 
Residual 6612972 91 72670   
Total 7895377 104 75917     
 
APPENDIX 49. ANOVA FOR MEAN n3 CONCENTRATIONS. 
Source Partial SS df MS F Prob > F
Model 6663 13 512 4.6 0.0000 
Treatment 15.4 1 15.4 0.1 0.71 
Day 6551 6 1091 9.8 0.0000 
Treatment by day 92.6 6 15.4 0.1 1.00 
Residual 10157 91 111   
Total 16820 104 161     
 
APPENDIX 50. ANOVA FOR NORMALIZED MEAN n3 CONCENTRATIONS. 
Source Partial SS df MS F Prob > F
Model 6651 13 511 0.9 0.55 
Treatment 3.8 1 3.8 0.01 0.94 
Day 6551 6 1091 1.9 0.08 
Treatment by day 92.7 6 15.4 0.03 1.0 
Residual 51244 91 563   
Total 57896 104 556     
 
APPENDIX 50. ANOVA FOR NORMALIZED WEIGHT DISTRIBUTION (FORCE PLATES). 
Source Partial SS df MS F Prob > F
Model 126 7 18.1 1.44 0.25 
Treatment 32.7 1 32.7 2.61 0.12 
Day 40 3 13.5 1.08 0.38 
Treatment by day 60 3 20.1 1.61 0.22 
Residual 225 18 12.6   
Total 351 25 14.1     
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